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ABSTRACT 
 
Development of a Bio-Sensing Technique for the Detection of Prions in Foods. 
(December 2003) 
Ashish Anand, B.Tech. , Kanpur University 
                      Chair of Advisory Committee: Dr. Rosana Moreira 
 
                  
An affinity based bio-sensing technique was developed using an anti-
transmissible spongiform encephalopathy monoclonal antibody as a bio-
recognition molecule. Fluorescein iso-thio-cynate (FITC), labeled with a prion 
epitope (QYQRES), was used as a decoy for prions. Experiments done in 0.1M 
phosphate buffer revealed that the dye fluorescence increased with the pH of 
the buffer and was influenced by solvent polarity.  
Binding studies conducted at pH 6, 7, and 8 showed that the optimum pH 
for the antibody-decoy binding was 7. Maximum differences between control and 
antibody samples were observed at pH 7. The optimum incubation time was 
found to be less than 4 hours for the control, antibody, and the prion samples at 
room temperature. Prion detection curves were established at 4 and 10 nM 
antibody decoy concentrations. The lowest detectable prion concentration in 
phosphate buffer was 8 nM. 
Experimental conditions determined in the phosphate buffer were used to 
implement the technique in gelatin and baby formula. Prion detection curves 
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were generated in 0.01, 0.4, 1.0 and 2.0 mg/ml of gelatin solution. The gelatin 
interfered with the binding and the displacement reaction of antibody, decoy and 
prion. Addition of an anionic surfactant, sodium dodecyl sulfate (SDS) at 0.3 
mg/ml to gelatin samples facilitated prion detection in gelatin. The lowest 
detectable concentration of prion in gelatin was 0.5 nM at 0.4mg/ml gelatin. The 
baby formula samples produced light scattering and the intrinsic peak of baby 
formula at 526nm interfered with the dye peak at 514nm. Serial dilutions of baby 
formula were done to reduce the interference. Prion detection curves were then 
obtained at 1.31 and 5.34 mg/ml baby formula and 0.454 mg/ml of Triton-X-100 
was added to the baby formula samples. The lowest detectable concentration of 
prion was 2 nM for baby formula. 
This developed bio-sensing technique can be used to detect prion in 
gelatin and baby formula solutions. Addition of surfactants assisted prion 
detection in foods, while high concentrations of gelatin and baby formula had an 
adverse effect on the detection system. 
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CHAPTER I 
INTRODUCTION 
Few diseases have captured both scientific and public attention this 
decade and among all of them, one of the most fatal neurodegenerative 
disorders is classified as Transmissible Spongiform Encepahlopathy. The 
transmissible spongiform encephalopathy (TSEs) (in both human and animals) 
has been studied with lot of emphasis on bovine spongiform encephalopathy 
(BSE) because of the spread of the disease in cattle, which also killed many 
people in the United Kingdom (‘mad cow disease’) (Fishbein, 1998). 
 BSE first appeared in the UK in 1985 (Brenig, 2001) and since then it has 
effected human life at health, scientific, economical, political, and judicial levels 
(Bounias, Purdey, 2002). In the UK BSE was known as a scrapie-like disease 
with the presence of characteristic lesions in the brains of affected cattle and the 
appearance of neurological disorders in cattle (Fishbein, 1998).  
It is reported that from 1988-1997 170,000 cases of BSE had been found 
in over 34,000 farms in the UK. It has been speculated that more than a million 
cattle infected with BSE may have entered the food chain (Anderson et al., 
1996).  
 
This Thesis follows a format and style of Journal of Food Engineering. 
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Over 140 patients with variant Creutzfeldt-Jakob disease (CJD) have died 
since 1995, probably by consuming BSE infected processed meat. Although 
most of the cases were reported in Great Britain, France, and Italy future cases 
may appear in any country where BSE exists, (Brown et al., 2003). No case has 
been reported in USA till date. 
The infectious agent behind TSEs/ BSEs is a misshapen protein called 
prion (PrPSC), typically found in the brain and spinal cord tissue. The prion 
protein that causes the transmission of TSEs is formed by the post translational 
and conformational change in the normal prion protein (Hope and Manson, 
1991; Prusiner, 1982; Prusiner, 1991).  
This protein could accidentally be mixed with foods such as sausages, 
meat in ground beef, etc. Some detection techniques are available to test 
abnormal prions in the brain of slaughtered animals, but there are no tests 
available to detect prions in food products. Prions are highly stable, they resist 
extreme conditions involved in food processing as freezing, high temperature 
pasteurization, and drying. 
Changing feed policies and monitoring animal diet can control epidemic in 
animals, but in case of humans BSE has an unknown incubation period before 
infection becomes evident. Hence, the only way to protect the US food supply 
chain from BSE is to develop a rapid and accurate detection technique for prions 
in foods. No information is available in the literature for the detection of prions in 
more complex matrices like foods. Unpredictable interactions of bio-molecules 
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present in foods with anti prion antibodies can pose serious challenges to the 
current detection techniques. 
 
The Food and Drug Administration (FDA) identified the need to develop a 
detection technique for BSE in foods and this research is aimed at developing a 
biosensor for prions. 
The objective of this research was to develop a biosensor to detect prion 
and prion peptides in different food materials. The detection technique utilizes 
the principle of competitive immuno assay in conjunction with fluorescence 
spectroscopy. This sensing technique requires less time and relatively moderate 
skills 
Specific aims of this research were: 
1. Development of a biosensor for the detection of BSE (prion and prion 
peptides) in buffer. 
2. Implementation of biosensor in food systems like gelatin and baby formula 
for the detection of BSE. 
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CHAPTER II 
LITERATURE REVIEW 
2.1 Prion Biology and Structure1 
 Prions are proteinaceous, infectious particles that are composed largely 
if not entirely, of an abnormal prion isoform designated PrPSC. The PrP gene 
encodes both PrPSC and the cellular isoform PrPc by a posttranslational process 
(Prusiner, 1991). The transformation of PrPC into PrPSC involves a profound 
conformational change (Riesner et al., 1996). The PrP molecule has two 
domains that play different roles in the conversion of PrPC into PrPSC (Figure1) 
(DeArmond and Bouzamondo, 2002). First, there is a stable or ordered core 
domain that contains PrPs two asparagine- linked oligosaccharides; two A-
helices, designated helix-B and helix-C, that are stabilized by a disulfide bridge 
between Cys179 and Cys214; a phos-phatidylinositol glycolipid (GPI) attached to 
the C-terminus at residue 231 which anchors PrPC to the plasma membrane; 
and the protein X binding sites, which are believed to lower energy barrier for 
conversion of PrPC to PrPSC when PrPC binds to the protein X (Kaneko et al.,  
1997; Telling et al.,  1995). Secondly, there is a variable or disordered domain 
that contains the portion of PrPC that interacts with PrPSC and changes its 
conformation from primarily unstructured in the former to β-sheet in the latter 
(Figure 2) (Prusiner et al., 1998). 2
 
                                                 
1 Parts of section 2.1, 2.2 and figure 1, 2 are reprinted with permission from Toxicology, 181-182, 
DeArmond, S., Bouzamondo, E., Fundamentals of prion biology and diseases, 9-16, copyright (2002) with 
permission from Elsevier. 
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PrPSC is distinguished from PrPC by its high β-sheet content, (PrPSC is 
about 30% α-helical and 43% β-sheet and PrPC is 42% α-helical and 3% β-
sheet) (Figure 2) (Pan et al.,1993), protease resistance and insolubility (Baldwin 
et al.,  1994; Pan et al., 1993; Pruisner et al.,  1983; Safar et al., 1993). Limited 
proteolysis purification techniques suggest that the apparent molecular weight of 
PrPSC is 27-30KDa. Proteolysis of PrPSC produces an N-terminal truncated 
protein designated as PrP 27-30 under conditions in which prion infectivity is 
retained (Riesner et al., 1996). PrP 27-30 forms rod-shaped polymers with the 
tinctorial properties of amyloid that are referred to as prion rods (Prusiner et al., 
1983). Electron microscopy suggests that prion rods are 20-30 nm in diameter 
and 50-120 nm in length (Nguyen et al., 1995). Treatment of prion rods with the 
detergents and solvents increased α-helix content of PrPSC and resulted in a 
substantial reduction in scrapie infectivity (Gasset et al., 1993; Safar et al., 
1994). It has been postulated that aggregation of prion leads to its infectivity. 
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Figure 1: Structure model of PrPc molecule. PrPC shown is attached to the plasma membrane by 
its GPI anchor to indicate how the range of movement of the N-terminal half of the molecule 
might be constrained in vivo. The putative protein X binding sites are indicated with an X with 
lines pointing to the discontinuous epitope on helices C and B with which it interacts (Kaneko et 
al., 1997; DeArmond et al., 2002). 
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Figure 2: Models of normal PrPC and abnormal PrPSC deduced from Syrian hamster 
recombinant PrP 90-231 (Prusiner, 2001). 
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Figure 3: Redrawn Schematic of the interaction of the N- terminal half of PrPC with the N- terminal 
half of PrPSC that results in the conversion of the non-infectious prion into infectious prion. 
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2.2 Why Does Prion Disease Occur1 
 There are four major reasons for the existence of prion diseases 
(DeArmond and Bouzamondo, 2002). First, the mature, full-length prion protein 
molecule can exist in two conformations (PrPC and PrPSC) without an additional, 
demonstrable chemical modification (Prusiner et al., 1998). Secondly, regardless 
of its origin, PrPSC can interact with PrPC and cause the latter to adopt an 
identical β-sheet conformation which, in doing so, initiates a self perpetuating 
process that results in geometrically increasing PrPSC concentrations and 
increasing prion infectivity titers in the brain (Figure 3) (Cohen et al., 1994; 
Jendroska et al., 1991).  
Thirdly, some mutations of and some insertions in the prion gene cause small 
amounts of PrPC to convert spontaneously to PrPSC, which accounts for the 
familial CJD and FFI (Fatal Familial Insomnia) categories of human prion 
diseases (DeArmond and Bouzamondo, 2002). Fourthly, it was recently 
discovered that other mutations of the prion gene expressed in transgenic mice, 
specifically those that cause GSS (Gerstmann Syndrome) like syndromes cause 
small amount of PrPC to adopt a pathogenic transmembrane topology (Hegde et 
al., 1998; Hegde et al.,  1999). There is not much information available on the 
concentration of prion necessary for disease transmission. Hence in a safe food 
supply chain there should not be any traces of PrPSC. 
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2.3 Current Detection Methods for BSE 
 Methods used for the detection of BSE are Western Blot, ELISA and 2-
site sandwich assay (Grassi et al.,  2000; Osech et al.,  2000; Meyer et al.,  
1999) (Table1). Detection limits for these immunological methods are at 
100pg/ml (approximately 40fM), which is sufficient to detect PrPSC in the infected 
animals (Grassi et al., 2000).  
No data is available to suggest that picomolar level of detection is good 
enough to prevent disease transmission after ingesting prion-contaminated food. 
An amplification procedure developed by (Saborio et al., 2001) on the basis of 
cyclic incubation and sonication of brain homogenates contaminated with PrPSC 
mixed with homogenates of uninfected animals can increase the concentration 
of PrPSC up to 100 fold. This procedure has not been tested in food products. 
Detection of prions using above mentioned immunochemical techniques 
is more accurate than the histological examination of the brain. Many polyclonal 
and monoclonal anti-PrP antibodies have been developed with the aim of 
increasing sensitivity and specificity, but none of them are able to distinguish 
between PrPC and PrPSC. As a result there is a need of pre-treatment with 
proteases to remove or degrade PrPC (Ingrosso et al., 2002). Among all the 
immunological methods, Western blotting is the best-characterized and widely 
validated technique. It has many disadvantages which include: lengthy 
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Table 1:  
Current detection techniques for PrPSC (Ingrosso et al., 2002) 
 
Technique Operation Principle Detection Method Detection 
Limit 
References 
Western Blot SDS-PAGE, electroblot on a 
membrane, and the use of 
molecular sizes of prion. 
Chemiluminescence 10-20pM (Wadsworth et 
al., 2001); 
(Zanusso et al., 
2002); Lee et al., 
2000) 
ELISA  
PrPSC absorption onto an 
ELISA well; incubation with 
anti-PrP specific primary and 
secondary antibodies. 
Chemiluminescence 2pM (Deslys et al., 
2001); (Grassi , 
2001) 
DELFIA/CDI PrPSC absorption onto a 
plastic well; incubation with 
anti-PrP specific primary 
secondary antibodies. 
Fluorescence 0.2-2pM (Safar et al., 
1998); (Volkel et 
al., 2001) 
FCS PrP is tagged by two 
fluorescent antibodies; highly 
fluorescent aggregates of 
PrPSC are detected by 
confocal microscopy. 
Fluorescence 2pM (Giese, 2000; 
Bieschke, 2000) 
MUFS Conformation- specific 
emission scan of aromatic 
residue of Prp. 
Fluorescence In pM (Rubenstein et 
al., 1998) 
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procedure and not many samples can be done in a single gel (Ingrosso et al., 
2002; Kuczius and Groschup, 1999). Many of these limitations are eliminated by 
techniques like the sandwich enzyme linked immunoabsorbent assay (ELISA) 
(Deslys et al., 2001; Biffiger et al., 2002). 
Dissociation-enhanced lanthanide fluorescence immunoassay/ 
conformation- dependent immunoassay (DELFIA/CDI) is an advanced 
immunoassay with an ELISA where the detection system is sensitive time-
resolved lanthanide fluorescence instead of chemiluminescence (Safar et al., 
1998; Macgregor and Drummond, 2001; Volkel et al., 2001). Detection limit 
using this method can be as low as picograms of PrPSC per ml therefore it is one 
of the most sensitive techniques for the detection of prion. However, similar to 
other immunological detection techniques, DELFIA/CDI has a limitation to 
differentiate between non-infectious and infectious prion (Ingrosso et al., 2002). 
At present, there are only two methods that can prevail without the 
availability of specific anti PrPSC antibodies. One is the multi-spectral ultraviolet 
fluorescence spectroscopy (MUFS) (Rubenstein et al., 1998) and the other is the 
confocal dual-color fluorescence correlation spectroscopy (FCS) (Giese et al., 
2000; Bieschke et al., 2000). MUFS utilizes the presence of aromatic amino acid 
residues in the protein and identifies protein on the basis of their characteristic 
emission spectrum. Though no recent work has been done using MUFS, it is 
capable of discriminating cellular prion from the infectious one and various 
strains of PrPSC (Brown et al., 2001). FCS identifies single fluorescent molecule 
 13
as they pass through laser beam and the objective of confocal microscope with 
a photon counter. This technique needs very small sample volumes and it is 20 
times more sensitive than the Western blot (Bieschke et al., 2000). However 
results obtained from FCS need validation, as the instrument is not available in 
other laboratories. 
All the above-mentioned techniques are sensitive and selective for the 
detection of PrPSC, but there are limitations associated with them, Western blot 
is time consuming and requires high expertise (Ingrosso et al., 2002); 
DELFIA/CDI cannot differentiate between normal and pathological prion, no 
further development has been done in case of MUFS after 1998, therefore 
practical applicability of MUFS is doubtful in near future (Ingrosso et al., 2002). 
Hence it is imperative to develop an alternative rapid and relatively simple 
detection technique that can differentiate between infectious and non- infectious 
prions. 
2.4 Food Safety and BSE 
 Outbreaks of BSE in cattle and resultant deaths of more than 140 
individuals due to consumption of BSE infected beef have created great health 
concerns among consumers, scientists, and government officials. Hence it is 
imperative to protect the food supply chain with increased assurance and 
supervision (Fishbein, 1998). To protect the public health from the threat of BSE 
a number of guidelines has been issued by the World Health Organization 
(WHO), Organization International des Epizootes (OIE), the Food and 
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Agricultural Organization (FAO) as well as by national and regional governments 
and organizations (European Union) (Fishbein,1998). 
Basically these measures fall into three categories: (a) To avoid BSE-
contaminated animals and meat products entering the food supply chain or 
being used in the production of medicinal products; (b) to screen and supervise 
BSE and CJD; (c) to identify research areas and efficient  implementation of the 
findings (Dora, 1998).  
In the above context WHO-(1996) issued the following recommendations 
to protect the public health and ensure safety of the food supply chain: 
1. No part or product of any animal that has shown signs of transmissible 
spongiform encephalopathy TSE, or tissues, which are likely to contain 
BSE agent should enter the food chain. 
2. All countries should establish surveillance and compulsory notification of 
BSE. 
3. All countries should ban the use of ruminant tissues in ruminant feed. 
4. Gelatin and tallow are only considered safe if effective rendering 
procedures are used. 
5. Medicinal products and medical devices should be obtained from 
countries with no sporadic cases of BSE and measures recommended to 
minimize the risk. 
 
 15
On the basis of these regulations gelatin can only be considered safe if 
adequate measures have been taken during gelatin manufacturing. In the US, 
the source of raw materials for gelatin manufacture is exclusively from beef 
hides, beef bones, and pork skin. Therefore, food safety risk for the foods made 
from gelatin can be high if gelatin is contaminated with BSE. To minimize the 
risk of contamination for the products made from gelatin it is important to detect 
the presence of prions in gelatin.  
2.5 Gelatin 
 It is a common product with a wide field of application. Gelatin is used for 
quality improvements in foods and medicines. It also serves as a supplementary 
source of protein, stabilizer, and emulsifier. It is also used for flavor 
enhancement, clearing of drinks, and as a collagen source for dietetics 
(Fennema, O., 1996). 
Gelatin is manufactured by a controlled hydrolysis from protein collagen. 
Gelatin is composed of a unique sequence of amino acids. Unique features of 
gelatin are the high percentage of the amino acids glycine, proline and 
hydroxyproline (Figure 4). 
Production of gelatin can be summarized in the following steps: 
 16
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Gelatin molecules contain repeating sequences of glycine-X-Y triplets, 
where X and Y are proline and hydroxyproline amino acids. These sequences 
are accountable for the triple helical structure of gelatin and its capability to form 
gels by immobilizing water (Figure 5).  
1. Raw material for manufacturing is obtained from hidesplits and 
connective tissues and the bones of cattle. 
2. Bones are splintered into pieces of less than 12mm diameter. They are 
kept in hot water to reduce the fat content to 2% and then dried for 30 
minutes at 100°C (Schrieber and Seybold, 1993). 
3. Phosphate minerals are removed from cleaned pieces by treating them 
with 4% hydrochloric acid, at a pH below 1.5 allowing collagen structure 
to be intact. This process takes 5 days, and begins with an already used, 
more diluted hydrochloric acid, which is replaced by a fresh batch of HCl 
at the end of the treatment (Schrieber and Seybold, 1993). 
4. More than 90% of the gelatin won obtained from the cattle is treated 
additionally. It normally takes about 50days at pH greater than 12.5 to 
expose the cross connections between collagen molecules (Schrieber 
and Seybold, 1993). 
5. Once gelatin is extracted step by step with water of increasing 
temperature, it is sterilized at 140°C for 4 seconds (Schrieber and 
Seybold, 1993). 
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The agents of scrapie and BSE are extremely resistant to physical and 
chemical treatments. Infectious agent can survive extreme acidic conditions, 
more intense than present in gelatin production; they are also resistant to 
alkaline conditions and drying temperature. In a nutshell the procedures used for 
gelatin production can reduce the infectiousness of BSE-contaminated raw 
material but complete inactivation is not possible. Therefore, we need a sensitive 
detection technique that can sense prion during the various processing steps of 
gelatin. 
2.6 Collagen and Its Structure 
 Collagen is a protein, which is involved in the formation of connective 
tissue together with elastin and polysaccharides. It is also present in cartilage, 
tendons and ligaments. The shape of the collagen molecule is like a rigid rod, 
about 3000A° long, with a diameter of 14A° and a molecular weight of 
approximately 300,000 (Schwick and Heide, 1969).   
Collagen contains small amounts of tyrosine and no tryptophan. The most 
common amino acids are glycine, proline, and hydroxyproline (Schwick and 
Heide, 1969). The general structure of collagen contain polar and apolar regions 
following each other. The most important amino acid sequence is glycine-
proline-hydroxyproline and every third amino acid is generally glycine. The two 
different known peptide chains are; the alpha1- and the alpha2- chain, each 
consisting of about 1000 residual amino acids and differing little in their 
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sequence. The alpha1 chain contains five and the alpha2- chain seven subunits. 
The individual chains form a helix in which hydroxyproline and proline are turned 
outwards to avoid sterical imbalance (Secondary Structure) (Rich and Crick, 
1961). The collagen molecule contains three helices; two alpha1 and one alpha2, 
which are twisted around a common axis in the form of a triple helix (tertiary 
structure). Helix is stabilized by the hydrogen bonds of inner glycine residues 
and the covalent bonding (Bornstein, 1966). 
The quaternary structure of collagen (Fibrils) contains individual collagen 
molecule aggregate. Hydrogen bonds, van der Waal’s forces, and covalent 
bonds play important role in stabilizing the structure. 
Collagen is hydrolyzed into gelatin under certain denaturizing conditions, 
e.g. heating (Fessler and Bailey, 1966; Harding, 1965). The conversion into 
gelatin takes 30 minutes in a citrate buffer of pH 3.7 at 35°C. This leads viscosity 
reduction and breaking of collagen molecule into peptide chains (Figure 6 & 7) 
(Veis, 1964). 
2.7 Baby Formula  
Baby formula was first manufactured in Germany in 1867. The most 
common ingredients of formula were milk solids, wheat flour, malt flour and 
potassium bi carbonate. Nutrients requirements have changed a lot since 
1867.According to FDA in (1985) the current formulation should have protein, 
linoleic acid, fat, choline, carbohydrate, inositol, calcium, phosphorous,  
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Figure (6): Redrawn collagen conversion to gelatin after heating for 30 minutes (Vies, 1964).  
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Figure (7): Redrawn breakdown of the collagen molecules into its subunits (Schwick, 1999). 
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magnesium, iron, zinc, manganese, copper, iodine, sodium, potassium, chloride, 
vitamin A, D, E, K, thiamine, niacin, pyridoxine, cobalamin, folic acid, biotin, 
panthothenic acid, ascorbic acid . 
Most of the milk ingredients used in formulating a dry baby formula is 
used as supplements for protein, fat, carbohydrate etc. These ingredients are  
made of milk produced by cattle; therefore it would be prudent to develop a 
detection technique for BSE (prions) in baby formula. 
On the basis of the literature review it is evident that no data is available to test 
BSE in foods. Most of the available techniques are immunological and there 
compatibility with foods has not been tested. This research is focused on 
developing a detection technique that is rapid, user friendly, and can be 
implemented into food systems like gelatin and baby formula.  
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CHAPTER III 
                                   BIOSENSOR SCHEME 
3.1 Macromolecule – Ligand Interactions 
 The role of every protein is related to its capacity to bind ligands (Brand 
et al., 1997). Binding of ligands to protein alters the three-dimensional structure 
and it influences the environment of an intrinsic or extrinsic fluor in the protein. 
These changes in structure can lead to quantifiable changes in the fluorescence 
spectrum (Sheehan, 2000). There are two possibilities s that can be used to 
investigate protein-ligand interactions. Either the fluorescence of the protein can 
alter on binding, or the fluorescence of the bound ligand can change. The 
changes in the fluorescence of a protein may be, due to one or more of the 
intrinsic tryptophan residues, because emission from this amino acid generally 
dictates the fluorescence of proteins. The other possibility is that the ligand 
fluorescence changes on binding. These changes can be accredited to energy 
transfer mechanism or by physical interaction of ligand with the protein and 
leading to change in the polarity of its surroundings. 
Fluorescent probes to detect the presence of target analytes are commonly used 
in immunoassays (Perez-Luna et al., 2002). In general, an antibody, is required 
which interacts with the antigenic analyte followed by incubation with a labeled 
Detection of the target analyte can be done by bringing in labeled analogs of the 
analyte that compete for the same binding sites on the antibody (Competitive 
immuno-assay) (Perez-Luna et al., 2002). In general, an antibody, is required 
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which interacts with the antigenic analyte followed by incubation with a labeled 
reagent (Udenfriend, 1962; Kress – Rogers, 1997). 
3.2 Antibody Their Structure and Function 
 Antibodies or immunoglobulin come under the category of glyco-proteins. 
They are produced by cells in response to an antigen. There are five major 
categories of antibodies, including IgG, IgD, IgA, IgE, and IgM (Steward, 1985).  
The basic structure of immunoglobulins is shown in (Figure 8). Although 
antibodies can differ in structure, but are made from the same basic unit (Voet et 
al., 2001).  
3.2.1 Heavy and Light Chain Antibodies have a Y shape structure as their basic 
unit. They are made of two identical light chains (Molecular weight 23 KD) and 
two identical heavy chains (Molecular weight 50-70 KD) (Steward, 1985).  
3.2.2 Inter Chain Disulfide Bonds Heavy and light chains with the two heavy 
chains are held together by disulfide bonds and by non-covalent interactions. 
The number of inter-chain disulfide bonds can be different among different 
antibodies (Steward, 1985). 
3.2.3 Intra Chain Disulfide Bonds They are present with in each of the 
polypeptide chains (Steward, 1985). 
3.2.4 Variable and Constant Regions Heavy and light chains are divided into two 
regions based on the differences in their amino acid sequences.  
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Light chain contains 110 amino acids in the variable and constant regions but 
heavy chain is made of 110 amino acids in the variable region and 330-440 
amino acids in the constant region (Steward, 1985). 
3.2.5 Hinge Region It is the region where arms of the antibody molecule form Y 
and is called the hinge region since the molecule is flexible at this point 
(Steward, 1985). 
3.2.6 Domains Three-dimensional structure of the antibody molecule reveals 
that it is not straight as shown in (Figure 8). Rather, it is folded into globular 
regions each of which has an intra-chain disulfide bond. These regions are 
called as domains (Steward, 1985). 
3.2.7 Oligosaccharides In most of the antibodies carbohydrate molecules are 
present in the constant regions; in some cases carbohydrates may also be 
attached at other locations (Steward, 1985). 
3.3 General Functions of Antibodies 
 Antibodies have two major functions, antigen binding and effector 
functions (Voet, Voet, 2001), (Steward, 1985). 
3.3.1 Antigen Binding Antibodies bind specifically to closely related antigens. 
Each antibody has specific affinity towards a specific antigen. Binding to 
antigens is the primary function of antibodies. The number of antigens an 
antibody can bind refers to the valency of the antibody. Valency of the antibody 
can be as low as two and in some instances more than two (Steward, 1985). 
 26
3.3.2 Effector Functions Sometimes binding of an antibody to an antigen has no 
direct biological significance. The noteworthy biological effects are result of 
secondary “effector functions” of antibodies. The antibodies facilitate different 
effector functions by interacting with its antigen. The general effector functions 
are complement fixation and binding to different cells (Steward, 1985). 
3.4 Antibody-antigen Interaction 
 The most important function of an antibody is form an antibody-antigen 
complex by interacting with its specific antigen. The interaction of antibody with 
the antigen results from the binding reaction of the binding site at antibody with 
the antigen. 
3.4.1 Intermolecular Forces in Antibody-antigen interactions These forces are 
similar to the forces involved in the stabilization of protein configurations. They 
contribute to the stabilization of the antibody-antigen complex. The forces 
present in antibody antigen interactions generally are hydrogen bonding, 
hydrophobic interactions, ionic or columbic interactions, Van der Waal’s forces 
and steric repulsive forces (Steward, 1985). 
3.4.1.1 Hydrogen Bonding Hydrogen bonding occurs when an H atom covalently 
linked to an electronegative atom with the unshared electron pair of another 
electronegative atom interacts. Amino or hydroxyl groups are the major 
hydrogen donors in antibody-antigen reaction (Steward, 1985). 
-O… H----O—, -O… H----N--, -N…H----N— 
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3.4.1.2 Hydrophobic Interaction Non-polar side chains of amino acids do not 
form hydrogen bonds with water. These groups prefer to interact with each other 
rather than with water—this is called as apolar or hydrophobic interaction. These 
bonds are stable due to change in the structure of the aqueous environment, 
which excludes water when groups come together. The involved proteins go to 
lower energy state and gain entropy, resulting in an attractive force between 
them. These forces are very important in antibody-antigen reactions (Steward, 
1985). 
3.4.1.3 Ionic Interaction The interaction between oppositely charged groups on 
two side chains is termed as ionic interaction 
  R----COO- …… +NH3----R 
Where R is the protein side chain. These forces do not play major role in the 
stabilization of antibody-antigen complexes (Steward, 1985). 
3.4.1.4 Van Der Waal’s Forces When the electron cloud of two polar groups 
interacts. On account of this interaction induction of oscillating dipoles happens 
in the two molecules, which leads to an attractive force. The Van der Waal’s 
forces vary inversely with the sixth power of the distance between the groups 
involved (Steward, 1985). 
3.4.1.5 Steric Repulsive Forces Steric repulsive force comes from the interaction 
between non-bonded atom’s electron clouds. Therefore, better 
complementarities of the electron cloud leads to lower repulsive force. This force 
is the leads to antibody discrimination. If the target analyte has an electron cloud 
 28
that is complimentary to that of the binding site, antibody will have low affinity for 
the antigen. Conversely, if the antigenic determinant and antibody are 
complementary then the antibody will have a high affinity because repulsive 
forces will be low (Steward, 1985). 
3.5 Measurement of Antibody-Antigen Reactions  
Generally, test for the measurement of antibody- antigen reactions 
depends on the interaction of the antibody with antigen, which leads to 
precipitation, which can be visualized in solution or gel. The reaction of an 
antibody (Ab) with an antigen (Ag) can be represented as follows: 
AgAbAgAb
ka
kd
*⇔+  
 Where ka is the association constant, kd is the dissociation constant. There are 
several methods are available to detect and quantify this interaction.  
Table 2: 
 
 Classification of antibody detection methods (Steward, 1985). 
Reaction  Analytical Method 
Primary Radio immnunoelectrophoresis 
Primary Farr binding 
Primary Antiglobulin technique 
Primary Fluorescence quenching, enhancement, polarization 
Primary Equilibrium dialysis 
Secondary Gel Diffusion 
Secondary P-80 radioprecipaitation 
Secondary Agglutination 
Secondary Complement Fixation 
Tertiary Passive cutaneous anaphylaxis 
Tertiary Arthus reaction 
Tertiary Immune elimination 
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3.5.1 Thermodynamics of the antibody-antigen reaction Binding affinity is the 
most important aspect of the thermodynamics of antibody-antigen reaction. 
Binding affinity refers to the strength of the interaction between an analyte and 
the antibody-binding site. Hence high affinity antibody refers to a strong complex 
formation with the antigen and visa versa. Affinity is a thermodynamic parameter 
and is expressed either in the form of equilibrium constant K or as the standard 
free energy ∆Gº. The expression relating antibody and antigen at equilibrium is 
given by the following equation: 
)*( AgAbAgAb
a
d
k
k
⇔+                                           (1) 
According to the Law of Mass Action, at equilibrium, the rate of forward reaction 
is equal to the rate of backward reaction 
)*())(( AgAbkAgAbk da =                                           (2) 
)])([(
)]*[(
AgAb
AgAbK
k
k
d
a ==                                             (3) 
Where K is equilibrium constant, ka is an association constant, kd is dissociation 
constant. 
Thermodynamic quantification of antibody antigen reactions requires that 
pure reactants in the solution. They should be homogenous with respect to 
antigens and binding sites. To meet these requirements monoclonal antibody is 
used, which in many cases behave ideally. Thermodynamic measurements with 
polyclonal antibodies are complexes because of their heterogeneous nature and 
multivalency for antigen.  
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Mass action model was used to determine the equilibrium constant in the 
present system of antibody-antigen reaction (Steward, 1985). Antibody—antigen 
reaction in the present biosensor falls under primary category and equilibrium 
conditions were measured by measuring the fluorescence intensity. 
3.6 Fluorescence Spectroscopy2 
 Light, a form of electromagnetic radiation, propagates by waves. Light is 
characterized by a wavelength and frequency. When light impinges upon matter, 
two things can happen: it can pass through the matter with no absorption, taking 
place, or it can be completely or partially absorbed. In the later case energy is 
transferred to the molecule in the absorption process. The absorption of energy 
must occur in integral units called, quanta. Every molecule possesses a series of 
closely spaced energy levels and can go from a lower to a higher energy level 
by the absorption of a discrete quantum of energy. Only a few molecules are 
raised to a higher excited state and hence are capable of exhibiting 
luminescence (Munck, 1989).  
3.6.1 Phenomenon of Fluorescence Luminescence is the emission of light from 
any substance and occurs from electronically excited states. Luminescence is 
divided into two categories, fluorescence and phosphorescence, depending on 
the nature of the excited state.  
3
                                                 
2  Section 3.6 is reprinted with permission Lackowicz, J., (1999) Principles of fluorescence spectroscopy, 
Plenum Publishers, New York, USA. 
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In fluorescence the electrons that are in excited singlet state (the electron 
in the excited orbital is paired opposite to the second electron in the ground state 
orbital) return to the ground state by emitting photon.  
The emission rates of fluorescence are typically 108 s-1, so that the typical The 
emission rates of fluorescence are typically 108 s-1, so that the typical 
fluorescence lifetime is near 10ns. Fluorescence typically occurs from aromatic 
molecules. Some typical fluorescent compounds are Quinine, Fluorescein, 
Rhodamine B, Acridine Orange, etc (Lakowicz, 1999). 
Phosphorescence is emission of light from triplet-excited states, in which 
the electron in the excited orbital has the same spin orientation as the ground 
state electron. Transitions to ground state are forbidden and the emission rates 
are slow, therefore phosphorescence lifetimes are typically milliseconds to 
seconds (Lackowicz, 1999). 
3.6.2 Fluorescence Life Times and Quantum Yields The fluorescence life times 
and quantum yield are perhaps the most important characteristics of a 
fluorophore. The quantum yield is the number of emitted photons relative to the 
number of absorbed photons. The higher the value of quantum yield, the greater 
the fluorescence of a compound. The lifetime is also important, as the lifetime 
determines the time available for the fluorophore to interact with or diffuse in its 
environment. The lifetime of the excited state is defined by the average time the 
molecule spends in the excited state prior to return to the ground state 
(Lakowicz, 1999). 
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3.6.3 Fluorescence Spectrum Any fluorescent molecule has two characteristics 
spectra: the excitation spectrum (the relative efficiency of different wavelengths 
of exciting radiation to cause fluorescence) and the emission spectrum (the 
relative intensity of radiation emitted at various wavelengths).  
The shape of the excitation spectrum should be identical with that of the 
absorption spectrum of the molecule and independent of the wavelength at 
which fluorescence is measured. However, due to instrumental artifacts these 
two spectrums are seldom the same. A general rule of thumb is that the longest 
wavelength peak in the excitation spectrum is chosen for excitation of the 
sample. This minimizes the possible decomposition caused by the high energy, 
shorter wavelength radiation. Emission spectrum of a compound results from the 
re-emission of radiation absorbed by the molecule. Quantum efficiency and 
shape of the emission spectrum is independent of the wavelength of the exciting 
radiation (Lakowicz, 1999). Fluorescent compound used in this study was FITC 
(Fluorescein Isothiocyanate), which has excitation wavelength at 493nm and 
emission wavelength at 514 nm. 
3.6.4 Fluorescence Measurements Fluorescence measurements can be broadly 
classified into two types, which are steady state and time resolved. Steady-state 
measurements are those performed with constant illumination and observation. 
This is the most common type of measurement. The sample is illuminated with a 
continuous beam of light, and the intensity or emission spectrum is recorded. 
Because of the nanosecond timescale of fluorescence when the sample is 
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exposed to the light, steady state is reached immediately. In case of time 
resolved measurements, the sample is exposed to a pulse of a light, where the 
pulse’s width is typically shorter than the decay time of the sample. The intensity 
is recorded with a high –speed detection system (Lakowicz, 1999).In the present 
detection system, fluorescence measurements were done when steady state 
was reached.  
3.6.5 Relation between Fluorescence Intensity and Concentration The basic 
equation, which relates fluorescence intensity to, the concentration of the 
compound, is following: 
bceIF εφ −−= )1(                                               (4) 
Where φ is the quantum efficiency, I is the incident radiant power, ε is the molar 
abosrptivity, b is the path length and c is the molar concentration. On the basis 
of the above equation, there are three major factors other than concentration 
that affect the fluorescence intensity- quantum efficiency, intensity of radiation, 
and molar absorptivity (Lakowicz, 1999). The principle of fluorescence 
spectroscopy can be summarized as follows: An incident beam of radiation of a 
given wavelength is passed through a sample cuvette containing the fluor. A 
photomultiplier tube detects emitted radiation at 90° to the direction of the 
incident light beam and a monochromator is required to select wavelength of the 
emitted light (Sheehan, 2000) (Figure 9). 
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3.7 Fluorescence Based Assay for the Detection of Prions 
 Fluorescent dyes have many advantages as sensing probes to study 
protein-ligand interactions. Commonly, dyes are useful because they are 
sensitive to the conformation changes and changes in the surroundings (Stryer, 
1968). This trait of extrinsic dyes can be exploited to sense the changes in the 
microenvironment. These transformations in dye can be seen as absorption 
characteristics or fluorescence emission spectra of a fluor. Some extrinsic dyes 
are nonfluorescent in aqueous (Polar) solution, but become fluorescent in a 
hydrophobic (Non polar) environment (Lopatin, 1971). A good example of this 
behavior is ANS (Anilinonaphthalene-1- Sulfonate) that has strong fluorescence 
in the hydrophobic regions of proteins where the unbound dye is non- 
fluorescent (Parker, Osterland, 1970). Another property of extrinsic dyes, which 
can be exploited in detecting the local environment changes, is their sensitivity 
to the pH change. An example of this type of dye is FITC (Fluorescein 
isothiocyante). Change in the fluorescence intensity of FITC due to pH change 
can be seen in (Figure10). 
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Figure 9: Redrawn schematic diagram of an ultra violet spectrofluorimeter. Light  
 wavelength (λ1) is absorbed by the sample in the cuvette. Emitted light of longer 
 wavelength (λ2) is passed through a monochromator and detected (Sheehan, 2000).
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Figure 10: Redrawn comparison of pH-dependent fluorescence of the oregon green 488, 
carboxy-fluorescein and alexa fluor 488 fluorophores. Fluorescence intensities were measured 
for equal concentrations of the three dyes using excitation/emission at 490/520 nm 
(www.molecularprobes.com). 
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These effects (hydrophobicity or pH) will be used to design an assay 
based on the change in fluorescence of the dye bound to antibody. It can be 
predicted that following reactions will take place in the detection system— 
)*( DAbDAb ⇔+                                              (5) 
)2*()*( DAbDDAb ⇔+                                          (6) 
  Where Ab is the antibody, D is a dye molecule attached with to a prion epitope, 
which binds to the antibody. Ab*D and Ab*D2 are antibody dye complexes. 
The fluorescence of the antibody dye complexes is different from the dye 
alone. Change in the fluorescence intensity of the dye upon binding to antibody 
can be attributed to the change in the local atmosphere (hydrophobicity or pH 
change) of the bound dye. It was assumed that two dye molecules can bound 
per antibody molecule, binding affinity of one or two dye molecules will be the 
same and the presence of second dye molecule will not effect the fluoresecence 
of antibody dye complex. 
3.8 Detection System 
 On the basis of above mentioned model, change in the fluorescence 
intensity was utilized to detect the molecule of interest (prion). The principle of 
the system can be summarized as: 
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1. Anti-prion antibody was incubated with the dye attached to a prion epitope 
(QYQRES). The prion epitope bound specifically to the binding site of 
antibody. 
2. Fluorescence of the sample was measured in the absence of prion. 
3. In the presence of excess analyte molecule, the dye molecule was 
displaced from the binding site of antibody (Competitive Immuno Assay). 
4. Fluorescence of the sample was measured again in the presence of prion. 
5. Change in fluorescence (The dye was not in the close vicinity to the 
antibody so hydrophobicity or pH change should not affect the fluorescence 
of dye). Intensity was used to relate the presence and concentration of prion 
in the samples. 
 
3.9 Schematic Diagram of the Biosensor 
 The detection system described above can be represented in a diagram. 
Following diagram represents the bio-sensing strategy used for detecting prion 
in foods (Figure 11): 
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Figure 11: Biosensor scheme. 
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CHAPTER IV 
MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Antibody- Anti TSE monoclonal antibody derived from the cell line 
F99/97.6.1 was procured from VMRD, Inc. (Pullman, WA, USA). 
4.1.2 Prion Protein- Lyophilized samples of prion peptides (prion protein, His 
Tag. Bovine, Recombinant E.coli) were obtained from BioSciences, Inc. (LaJolla 
CA, USA). 
 4.1.3 PrP epitope labeled FITC- Labeled Fluorescein (FITC-GABA-QYQRES) 
was custom made by Multiple Peptide Systems (San Diego, CA, USA). 
4.1.4 Chemicals- Sodium phosphate, sodium azide, sodium dodecyl sulphate 
(SDS), Triton-x-100. These chemicals were used in buffer preparation; they are 
available at Sigma Chemicals (St. Louis, MO, USA). Protein A column from 
(Amersham Biosciences, NJ, USA). 
4.1.5 Baby Formula- Good Start Brand Nestle (Los Angeles, CA, USA). 
4.1.6 Gelatin- Unflavored gelatin powder manufactured by Knox (Glen View, IL, 
USA). 
 
4.2 Reagent Preparation  
4.2.1 Buffer Solution- 0.6 gm of monobasic sodium phosphate was added to 50 
ml distilled water; 0.01% sodium azide was added to prevent microbial 
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contamination in the buffer. The solution was mixed well on a rotator for 10 
minutes and the pH was adjusted to 7 ±0.01 using HCl/ NaOH. 
 4.2.2 Decoy Solution- Stock solution of decoy (FITC dye and prion epitope) was 
prepared by dissolving the dye into the buffer; serial dilutions were done to 
obtain the desired concentration of decoy in the final samples. The pH of the 
decoy was checked frequently to ensure it is fixed at 7± 0.01. 
4.2.3 Antibody- The antibody was purified using affinity chromatography on an r 
protein A column. 2mg/ml of bovine serum albumin (BSA) was added to the 
antibody for stabilization during storage. Dilution of antibody was done using 
phosphate buffer. The molecular weight of antibody used for calculations was 
150,000 Daltons. 
4.2.4 Gelatin Solution- Gelatin solution was prepared by dissolving powdered 
gelatin and SDS (Sodium Dodecyl Sulphate) in 0.1M sodium phosphate buffer. 
The solution was kept in a water bath at (35-40ºC) and shook intermittently to 
prepare a clear solution of gelatin with no lumps. The pH of the solution was 
adjusted by adding very small amounts of acid (0.1M HCl) or base (0.1M 
NaOH). Depending on the final concentration of gelatin in the samples, the stock 
concentration was adjusted. SDS concentration was fixed at 0.3mg/ml in the 
gelatin samples. Fresh solution of gelatin with SDS was prepared for all the 
experiments to avoid any kind of microbial contamination. 
4.2.5 Baby Formula Solution- Stock solution of baby formula was prepared by 
adding 29 gm of dry formula in 100 ml of 0.1M phosphate buffer. The 
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temperature of the buffer was adjusted to 35-40ºC by keeping it in a water bath. 
The solution was kept on a tumbler for 3-4 hours to achieve a homogenous 
solution. Final pH was adjusted to 7±0.01 by adding very small amounts 0.1M 
HCl or 0.1M NaOH. Fresh stock of baby formula solution was prepared for all 
the experiments to avoid microbial contamination. Serial dilutions of baby 
formula were done using phosphate buffer only. Extent of dilution was 10 times, 
20 times, 40 times, and 5000 times for different experiments. 0.454 mg/ml of 
Triton-X 100 was added to the final baby formula samples. 
 
4.3 Fluorescence Measurement  
Changes in the fluorescence intensity were measured by testing the 
following samples: 
4.3.1 Control Sample- Buffer (0.1 M Sodium Phosphate) and labeled analog of 
target analyte (decoy). 
4.3.2 Antibody Sample- Buffer, decoy and anti-prion antibody. 
4.3.3 Prion Sample- Buffer, decoy, anti-prion antibody and prion. 
On the basis of previously mentioned hypothesis, increase in the 
fluorescence signal of antibody sample from control sample was due to pH 
change or to hydrophobicity. The prion sample intensity was close to the control 
value since the prion will displace the entire bound decoy from the antibody 
(Competitive Immuno Assay). Differences in intensity were used to calculate the 
concentration of prion in the sample. 
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4.4 Testing Procedure 
 Anti-prion antibody diluted in buffer (0.1M Sodium phosphate) was used 
for competitive immunoassay. Labeled analog of target analyte (decoy) (FITC-
GABA-QYQRES) was diluted using the same buffer. 
 A control sample was prepared by adding decoy and buffer. Antibody sample 
was made by adding decoy and antibody in 1:1 ratio and adding buffer to make 
up the rest of the volume. 
 All the samples were covered with aluminum foil to prevent photo bleaching of 
the dye. The samples were placed on a rotator for 4 hours for the reaction to 
reach equilibrium. 
 After the reaction reached equilibrium, the fluorescence of control and antibody 
samples was measured using a spectrometer (Photon Technology International. 
Lawerenceville, NJ, USA). 
 Once the decoy was bound to the antibody-binding site, prion was added in an 
increasing ratio to decoy for different samples. The samples were kept on a 
rotator for 4 hours to reach equilibrium.  
 Fluorescence of the prion samples was measured again after the reaction 
reached equilibrium. 
 Differences in fluorescence intensities of decoy before and after addition of the 
target analyte were used to detect the presence of prion in the sample. 
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4.5 Optical Setup  
Experimental data was collected using a fluorescence spectrometer 
(Photon Technology International, Lawerenceville, NJ, USA) that has PTI 
fluorescence system hardware and Felix for Windows software. Excitation 
source for spectrometer was an Argon laser (488nm) from Spectra Physics, 
(Houston, TX, USA). 500nm cutoff filter was also placed at the exit slit of the 
fluorometer. Square quartz cuvets Fisher Scientific, Pittsburgh, (PA, USA) size 
10×10mm were used for testing the samples in the spectrometer. 
 Experiments were done for different concentrations and fixed ratio of 
antibody and decoy. Prion peptides were added at different concentrations to 
find the optimum range in which maximum change in fluorescence can be 
obtained. Most of the initial testing was done in phosphate buffer until the range 
of conditions that work well for the detection of prion was found. Similar 
experiments were done in food products to examine prion displacement. The 
experimental data was used to develop a mathematical model that can be used 
to determine the equilibrium constant for antibody decoy reaction.  
All the experiments were done in triplicates and statistical analysis was 
done using statistical software SPSS (Version 11.0 for Windows). 
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CHAPTER V 
RESULTS AND DISCUSSION 
 
5.1 Effect of Environmental Changes on Dye Fluorescence  
Generally extrinsic dyes are sensitive to the structural changes and 
change in their local environment. These changes can be used to study the 
microenvironment (Lopatin, 1971). Some dyes like ANS are sensitive to the 
polarity of the solution; ANS strongly fluoresces when bound to the hydrophobic 
regions of the protein while unbound dye is non-fluorescent (Lopatin, 1971). 
Another property of extrinsic dyes is their sensitivity to the changes in their local 
environment pH. A good example is fluorescein. 
 Fluorescein Isothiocyanante (FITC) is sensitive to the pH of the solvent 
and Figure (12) shows the dependence of FITC on the pH. As the pH of the 
buffer was increased from 5 to 9 the fluorescence intensity of the dye also 
increased to a maximum value. At pH 10 the value of Intensity decreased to a 
steady level. All the intensity values were significantly different at p<0.05. 
Emission of the fluorescence intensity of FITC is also dependent on the 
polarity of the environment. Figure (13) represents the affect of different solvents 
on the fluorescence intensity. The maximum intensity was observed in the polar 
solvents like 0.1 M phosphate buffer; hydrophobic solvent decreased the 
intensity of FITC. Intensity values are significantly different at p<0.05. These 
properties of FITC were exploited in probing changes in the microenvironment of 
antibody after antigen binding. The increase in fluorescence intensity of antibody 
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Figure 12: pH dependence of decoy in 0.1 M sodium phosphate buffer. Emission 
 peak was at 514 nm. Decoy concentration was 4 nM. Data analysis (Appendix A-1). 
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Figure 13: Effect of the polarity of solvent on dye fluorescence. Emission peak was  
at 514 nm. Data analysis (Appendix A-2). 
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samples can be based upon the following hypothesis: “After the dye is bound to 
the antibody there is a change in the local environment of the dye that leads to 
the measurable change in fluorescence intensity of the dye.” 
The change in the fluorescence can be attributed to the pH change or the 
hydrophobicity. In Figure (13), the fluorescence of the dye decreased in the 
more hydrophobic (intensity value is less in DMSO than ethanol) environment 
thus an increase in the fluorescence due to hydrophobicity is less likely. Hence, 
the change in the intensity can be attributed to the pH change. 
5.2 Binding Studies of Antibody to Decoy 
 From Figure (12) and (13) change in the fluorescence of the dye was 
observed due to a change in the surrounding environment of the fluorophore. An 
increase in the fluorescence upon binding of the decoy (dye and prion epitope) 
to the antibody is due to a change in the pH. From Figure (12), the maximum 
change in the intensity was observed between pH6 and 8 the, dynamic range of 
pH change.  
The maximum difference between the control and the antibody sample 
was observed at pH7 Figure (14). This may be due to the fact that in the control 
sample at pH 7 there is no change in the local pH of the decoy, but in the case 
of the antibody sample at pH 7 the local pH around the decoy advances towards 
9 upon binding with the antibody. The differences were significant at p<0.05. 
5.2.1. Equilibrium Studies To ensure that the effect observed upon the binding of 
decoy with antibody is stable and specific, more experiments were done to  
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Figure 14: Effect of buffer pH on the % difference of the intensity between the 
control and antibody samples. Peak was measured at 514 nm. Decoy 
concentration was 4 nM and antibody was added in 1:1to decoy. Data 
analysis (Appendix A-3). 
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determine the equilibrium conditions. Figure (15) illustrates that the reaction 
reaches equilibrium in less than 4 hours and the change in the intensity was 
specific for antibody and the decoy. From Figure (16) it is evident that the same 
effect was not observed when Bovine Serum Albumin (BSA) was used instead 
of the antibody. All the values were significantly different at p<0.05. 
Hence, the change in fluorescence of the decoy upon binding with the 
anti-TSE antibody is specific and the reaction reaches equilibrium in 4 hours. 
From this point onwards the incubation time for all the further experiments was 4 
hours at room temperature. 
5.2.2 Determination of Equilibrium Constant The equilibrium constant K, for the 
reaction between the antibody and the decoy was determined using Law of 
Mass action.  
Experimental data was obtained keeping decoy concentration constant at 10nM 
and antibody concentration was varied from 0 to 110nM. Fluorescence intensity 
of the decoy was measured and the data was analyzed using the following 
model to obtain the K value: 
DAbDAb *⇔+                                                (7) 
Equation (8) represents a general equilibrium reaction between antibody and 
decoy. The expression for the equilibrium constant on the basis of the mass 
action model was given as: 
                                      
]][[
)]*[(
DAb
DAbK =                                                                (8) 
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Figure 15: Equilibrium studies for antibody-decoy binding. % Difference represents  
intensity difference between control and antibody samples. Decoy concentration  
was 4 nM and antibody was added in 1:1to decoy. Data analysis (Appendix A-4). 
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Figure 16: Specificity of the antibody-decoy binding. Other protein (BSA) does not  
exhibit similar interactions. Decoy concentration was 4 nM and antibody was added in 1:1  
to decoy. Data analysis (Appendix A-5). 
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After applying mass balance on the total concentration of antibody and decoy 
following equations were obtained: 
)]*[( DAbAbAb OT +=                                              (9) 
)]*[( DAbDD OT +=                                           (10) 
Fluorescence intensity of control and antibody solutions was related to the 
concentration of the free and bound decoy in the solution. 
)]*[(][ DAbbDaI O +=                                            (11) 
][ TO DaI =                                                   (12) 
Equation (11) was rearranged and 
)]*[()]*([ DAbDAbDaI T +−=                                    (13) 
Equation (8) was also rearranged using equations (10) and (11): 
)]*()][*([
)]*[(
DAbDDAbAb
DAbK
TT −−
=                                 (14) 
Using equations (13) and (14) an expression was derived relating K and 
intensity of the solutions. 
   
K
KDKAbKDAbDKAbKDAb
D
ab
I
I TTTTTTTT
TO 2
22211)1/(1
2222 ++−++−++−+=         (15)                          
Equation (16) can be used to estimate equilibrium constant. The value of b/a 
was estimated as the ratio of intensities at zero and maximum antibody 
concentration. It was assumed that binding of one decoy does not affect the 
binding affinity of the other decoy to bind.  The value of the equilibrium constant 
was close to 1Χ109 Mole-1 at room temperature. Figure (17) presents the binding 
 54
affinity curve of the antibody at a fixed decoy concentration. The optimal 
operational range for the sensor is at low concentration values (<20 nM) before 
saturation effect is observed. 
5.3 Prion Studies in Buffer 
 To study the displacement of decoy with prion, samples containing 
antibody, decoy, buffer, and prion were tested against the control (buffer and 
decoy) and antibody samples (buffer, antibody and buffer). Intensity was 
measured for all the samples and the difference in intensity was used to detect 
the presence of prion. Table (3) represents the prion displacement. As the prion 
concentration increases the intensity of the prion sample should approach that of 
the control value. It is evident that at low concentration of prion (10 nM), the 
sample intensity was close to the control, but at 20 nM prion concentration there 
was an unexpected increase in the prion samples. 
 The possible reason for this behavior was the long incubation time (20 
hours) of the prion samples, which led to prion aggregation, since prions are 
known to aggregate at high concentrations (Gasset et al., 1993; Safar et al., 
1994). An increase in the intensity of the control samples with prion can also be 
attributed to prion aggregation (Table 4). Intensity values for prion controls (20, 
60, and 90 nM) were significantly different from 0 nM prion at p<0.05. 
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Figure 17: Binding affinity curve. Antibody concentration was varied from 0 to 110 nM  
and decoy concentration was fixed at 10 nM. At high concentrations of antibody 
 (>20 nM) saturation effect was observed. Data analysis (AppendixA-6). 
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Table 3: 
 Decoy displacement by prion. Concentration of decoy 10 nM, antibody concentration 10 nM, 
prion was added in the increasing ratio to decoy. Incubation time for all the samples was 20 
hours. Data Analysis (Appendix A-7). 
 
Sample Prion 
Concentration [nM]
Mean Intensities 
(Counts/sec) 
Intensity 
difference from no 
Prion sample 
Control - 40132.73 - 
Antibody sample  0 63613.30 0.00% 
Antibody and prion 10 56912.20 -10.53% 
Antibody and prion 20 74020.00 16.36% 
Antibody and prion 60 81498.63 28.11% 
Antibody and prion 90 108978.67 71.31% 
 
Control = Buffer + Decoy, Antibody = Buffer + Decoy + Antibody, Antibody and prion = Buffer + 
Decoy + prion 
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Table 4: 
 Mean intensity values of prion controls (buffer, decoy and prion). Incubation time for 
 samples were 20 hours. Data Analysis (Appendix A-8). 
 
Sample Mean Intensities 
(Counts/sec) 
Difference between no 
prion sample and 
control 
Control and 0nM prion 40132.73 0.00% 
Control and 10nM prion 43974.30 9.57% 
Control and 20nM prion 45185.03 12.58% 
Control and 60nM prion 49166.63 22.51% 
Control and 90nM prion 68122.73 69.74% 
 
Control = Buffer + Decoy, Control and prion = Buffer + Decoy + prion 
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 To reduce the risk of aggregation a kinetic study was done to determine 
the optimum incubation time for decoy displacement by the prion. From Table 
(3) and (4) it was evident that prion concentration higher than 50 nM leads to  
aggregation. Therefore the kinetic study was done at 60nM of prion. Figure (18) 
explains the results of the kinetic study. The maximum difference between prion 
and no prion samples was observed at 4 hours. Hence 4 hours are sufficient for 
the decoy to be displaced by prion. As the time increased, the intensity values 
for the prion sample increased again. From the above experiments it was 
evident that high concentration prion samples had an unusual behavior and 
measures should be taken to avoid prion aggregation in solution. More kinetic 
studies showed similar behavior for the prion samples.  
From this point onwards all the prion displacement experiments were 
conducted at low concentrations and incubation time for all the samples was 4 
hours. Figure (19) represents another decoy displacement study where 
incubation conditions were similar to the previous findings. The minimum 
detection concentration of prion was 8 nM at p<0.05. Samples from 8 nM 
onwards were significantly different from each other using LSD at p<0.05. The 
maximum detectable concentration of prion was 20nM in this experiment. There 
was no significant difference between 20 and 40 nM samples since most of the 
decoy was replaced by prion at 20 nM. Prion aggregation was not observed after 
4 hours of incubation.  
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Figure 18: Kinetic study for decoy displacement by prion. Percentage difference indicates 
 the intensity difference from control sample. Decoy concentration was 10 nM,  
antibody concentration was 10 nM and prion concentration was 60 nM. Data analysis  
(Appendix A-9). 
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Figure 19: Decoy displacement plot in 0.1M phosphate buffer. Decoy concentration  
4 nM, antibody concentration 4 nM, and prion was added in the increasing ratio to 
 the decoy. Data analysis (Appendix A-10). 
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On the basis of this experiment it was concluded that sensitivity of 
detection is between 8 nM and 20 nM of prion; after that saturation effect was 
observed. Prion was always added in an increasing ratio to decoy therefore to 
probe the lower detection limit of prion detection. Concentration of decoy was 
reduced from 4 nM to 1 nM. The lowest detectable concentration of prion in this 
experiment was 200 pM.  
Figure (20) shows the result of decoy displacement at 1nM decoy 
concentration. All the prion samples other than 5 nM were significantly different 
(p<0.05) from the no prion sample, which could be an experimental anomaly. 
Samples were significantly different from each other. There was a decrease in 
the fluorescence of the no prion sample compared to the control sample, which 
was not the case at 4 nM and 10 nM decoy concentrations. This behavior was 
consistent. It was hypothesized that at 1nM decoy concentration the binding 
affinity of antibody alters or the time taken to reach equilibrium conditions was 
different than the higher concentrations of decoy. Further investigation is needed 
to determine the equilibrium conditions at very low decoy concentrations. 
Prion detection experiments performed in phosphate buffer at the 
different concentrations of decoy revealed that prion could be detected using this 
biosensor. Detection limit was as low as 8 nM at 4 nM decoy concentration and 
200 pM at 1 nM decoy concentration. Since all the initial conditions for prion 
detection were determined in phosphate buffer, experiments were initiated to 
implement the same technique in food products. 
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Figure 20: Decoy displacement plot at 1 nM decoy concentration. Antibody concentration 
 was 1 nM and prion was added in the increasing ratio to the decoy. Lowest detectable  
prion concentration was 200 pM. Data analysis (Appendix A-11). 
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5.4 Prion Detection in Gelatin Solutions 
 Gelatin is a complex protein and its interactions with prion or decoy are 
not known. An initial prion detection experiment was done in low gelatin 
concentration to minimize the interaction of gelatin with other bio-molecules in 
the system. Figure (21) illustrates prion detection in 0.01 mg/ml gelatin solution. 
The lowest detectable concentration was 4nM at p<0.05 from no prion sample. 
The 4, 8 and 10 nM samples were significantly different from each other at 
p<0.05. 2 nM sample was not significantly different from the 0 nM prion sample.  
Figure (22) shows the decoy displacement in 0.4 mg/ml gelatin solution. 
In this case the lowest detectable concentration of prion was 2nM but, different 
prion concentration samples were not significantly different from each other. 
Only the 2, 8 and 10 nM samples can be differentiated from each other. Results 
from this experiment indicate that the dynamic range of detection is low in 0.4 
mg/ml gelatin solutions as compared to 0.01 mg/ml gelatin.  
A plausible explanation for this behavior could be that gelatin interferes 
with the binding of decoy to the antibody or with the displacement of decoy by 
prion. To minimize the interactions of free groups on the side chains of gelatin 
with other molecules in solution, a small amount of surfactant was added to the 
gelatin samples. Several classes of polymers interact strongly with surfactants; 
these interactions are electrostatic or hydrophobic in nature (Griffiths et al., 
1997).  
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Figure 21: Prion detection curve in 0.01 mg/ml gelatin. Decoy concentration was 4 nM 
, antibody concentration was 4 nM, and prion was added in the increasing ratio to decoy. 
 Data analysis (Appendix A-12). 
Intensity Ratio* is defined as the ratio of mean fluorescence intensities of prion samples 
 to the no prion sample/antibody sample. 
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Figure 22: Prion detection curve in 0.4 mg/ml gelatin. Decoy concentration was 4 nM, 
 antibody 4 nM; prion was added in the increasing ratio to decoy. Lowest detectable 
 prion concentration was 2 nM. Data analysis (Appendix A-13). 
Intensity Ratio* is defined as ratio of mean fluorescence intensities of prion samples  
to the no prion sample/antibody sample. 
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  Therefore weakly charged polyampholytes such as gelatin also form 
complexes with anionic surfactants, which stabilize the structure and free groups 
on the side chains of gelatin (Griffiths et al., 1997). 
The low dynamic range of prion detection in 0.4 mg/ml gelatin may be 
due to small differences between gelatin control and gelatin antibody samples 
Figure (22). Hence, to improve sensitivity of detection it is imperative to increase 
the differences between gelatin control and gelatin antibody samples. SDS 
(0.3mg/ml) was added to the samples and Table (5) shows the results. Addition 
of SDS increased the difference between gelatin control and gelatin antibody 
samples from 11% to 20%. The differences between average intensities were 
significant at p<0.05.  
On the basis this result, prion displacement experiment was repeated in 
0.4 mg/ml gelatin with 0.3mg/ml SDS. Addition of SDS to the gelatin samples 
improved the sensitivity of detection as well as the detection limit Figure (23). 
The lowest detectable prion concentration was 0.5 nM and the maximum 
detectable concentration was 5 nM. The 1nM prion sample was significantly 
different from 0.5 and 0.8 nM prion sample but, it was not significantly different 
from the 2, 5nM samples. This could be an experimental anomaly. The addition 
of SDS to the samples improved the dynamic range of detection from 0.5 to 5nM 
at p<0.05 Figure (23).  
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Table 5: 
 Effect of SDS on the differences between gelatin control and gelatin antibody samples.  
Data Analysis (Appendix A-14). 
 
Sample No. Tested Sample Average 
Intensity 
(Counts/sec) 
% Difference of 
intensity 
Coefficient 
of variation 
1 Control 104436.00 - - 
2 Antibody sample 129755.00 24.24  
3 Gelatin control 133127.67  2.55% 
4 Gelatin Antibody 
sample 
147980.67 11.16 3.23% 
5 Gelatin SDS 
control 
99916.47 - 1.08% 
6 Gelatin SDS 
antibody sample 
119617.33 19.72 1.87% 
 
Control = Buffer + Decoy, Antibody Sample = Buffer + Decoy + Antibody, Gelatin control  
= Buffer + Decoy + Gelatin, Gelatin antibody = Buffer + Decoy + Gelatin + Antibody,  
Gelatin SDS control = Buffer + Decoy + Gelatin + SDS, Gelatin SDS antibody sample 
 = Buffer + Decoy + SDS + Gelatin + Antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68
 
 
 
 
 
 
Prion Concentration [nM]
0 0.5 0.8 1 2 5
In
te
ns
ity
 R
at
io
* o
f P
rio
n 
to
 n
o 
Pr
io
n 
sa
m
pl
es
0.80
0.85
0.90
0.95
1.00
1.05
 
 
Figure 23: Prion detection curve in 0.4 mg/ml gelatin with 0.3 mg/ml SDS. Decoy  
concentration was 4 nM, antibody 4 nM; prion was added in the increasing 
 ratio to decoy. Lowest detectable prion concentration was 0.5nM. Data analysis 
 (Appendix A-15). 
Intensity Ratio* is defined as the ratio of mean fluorescence intensities of  
prion samples to the no prion sample/antibody sample. 
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Figure 24: Prion detection curve in 1.0 mg/ml gelatin with 0.3 mg/ml SDS. Decoy  
concentration was 4 nM, antibody 4 nM; prion was added in the increasing ratio  
to decoy. Lowest detectable prion concentration was 1.0 nM. Data analysis  
(Appendix A-16). 
Intensity Ratio* is defined as the ratio of mean fluorescence intensities of prion  
samples to the no prion sample/antibody sample. 
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Another experiment of prion detection with 1 mg/ml of gelatin and 0.3 
mg/ml of SDS was performed; Figure (24) illustrates the effect of high gelatin 
concentration on prion detection. In 1 mg/ml gelatin solution the lowest 
detectable concentration of prion was 1nM at p<0.05. Samples with 1, 2 and 
5nM prion concentration were significantly different from the no prion samples at 
p<0.05. It was evident that increasing the concentration of gelatin lowered the 
detection limit of the biosensor. High gelatin concentrations may adversely affect 
the sensitivity of prion detection. More investigation is required in this area. 
An odd problem was encountered when 2 mg/ml gelatin experiments 
were conducted. The response from the antibody was not the same as 
compared to the previous experiments. All the experimental variables like 
concentration of the solutions, pH of the buffer, and optical system were 
checked to ensure the consistency of the experimental setup. After eliminating 
all the possible variables it was concluded that the antibody was not in the same 
state as it was in the previous experiments. A SDS-PAGE gel done run to find 
the status of antibody and it was clear from the results that the antibody was not 
aggregated and it was in good condition. Purification of antibody was done using 
a protein- A column and the concentration of the antibody was found to be 0.5 
mg/ml instead of expected 1mg/ml Figure (25). 
Table (6) shows the effect of antibody concentration on the difference 
between the antibody and control samples. The difference between control and 
antibody sample increased as the ratio (antibody: decoy) was higher. 
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Table 6: 
Effect of antibody concentration on the difference between control and antibody sample. Decoy 
concentration was 4 nM. Data Analysis (Appendix A-17). 
 
Sample Antibody:Decoy Antibody 
Concentration 
[nM] 
Mean 
Intensities 
(Counts/sec) 
% 
Difference
Control (Buffer and 
Decoy) 
0 0 116385.00 0 
Antibody1 
(Buffer+Antibody+Decoy) 
1 2.0 124537.30 7.00 
Antibody2 
(Buffer+Antibody+Decoy 
1.6 3.2 125749.70 8.05 
Antibody3 
(Buffer+Antibody+Decoy) 
2 4.0 135077.70 16.06 
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Figure 26: Prion detection curve in 2.0 mg/ml gelatin with 0.3 mg/ml SDS. Decoy  
concentration was 4 nM, antibody 4 nM; prion was added in the increasing ratio 
 to decoy. Lowest detectable prion concentration was 2.0 nM. Data analysis  
(Appendix A-18). 
Intensity Ratio* is defined as the ratio of mean fluorescence intensities of prion 
 samples to the no prion sample/antibody sample. 
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The difference between mean intensities was significantly different at 
p<0.05. After appropriate adjustment in the antibody concentration similar 
response upon decoy binding from antibody was obtained. Figure (26) illustrates 
the decoy displacement study in 2 mg/ml gelatin and 0.3mg/ml SDS. The 
Minimum detectable concentration of prion was2 nM at p<0.05. There was no 
significant difference among the 0.5, 0.8 and 1.0 nM samples and no prion 
sample. The 2 nM and 5 nM prion samples were significantly different from each 
other at p<0.05. The sensitivity of the detection decreased as the concentration 
of gelatin was increased. At 0.4 mg/ml gelatin concentration, the sensitivity was 
0.5 nM of prion, which decreased to 2 nM at 2 mg/ml gelatin concentration. From 
the above results it is evident that the developed biosensor can be used to 
detect prion in gelatin solutions. Detection technique has limitations at high 
gelatin concentrations; however addition of SDS improves the differences 
among gelatin solutions. The detection limit using this technique can be as low 
as 0.5nM, which decreases to 2nM for 2 mg/ml gelatin concentrations. 
5.5 Dilution Studies in Baby Formula 
Baby formula is a very complex medium and it contains many different 
proteins, fat, carbohydrate and minerals. These ingredients in the baby formula 
work as a scattering medium for the incident light, which adversely affect the 
fluorescence and emission peak of decoy. To minimize the scattering from the 
baby formula, serial dilutions of baby formula were done and the linear range of 
decoy was determined in diluted formula samples. 
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Figure 27: Linear range of decoy in full strength baby formula. Full strength baby formula  
is 29 gms/100ml. 
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Figure (27) represents the variation of fluorescence intensity with the 
decoy concentrations in full strength baby formula. More variation in the intensity 
was observed at the low concentrations of decoy. To overcome this problem, the 
baby formula was diluted. From the preliminary scans of baby formula it was 
clear that full strength formula has a fluorescence peak at 526-528 nm. Due to 
this inherent fluorescence peak of the baby formula, the emission peak of decoy 
was not visible at high concentrations and decoy fluorescence was not stable. 
Figure (28) represents the scans of baby formula at different concentrations. As 
the strength of baby formula was reduced intensity of its peak dropped and the 
decoy peak was more visible. Therefore it was concluded that dilution of the 
baby formula was necessary to conduct the experiments at low concentrations 
of decoy. Figure (29) represents the linear range curve of the decoy in 20 times 
diluted baby formula solution. At low concentration of decoy a more stable signal 
was observed. Variation of the intensity was linear with the concentration with R2 
as 0.994. Other linear curves were generated at different concentrations of baby 
formula. 
5.6 Prion Detection in Baby Formula 
 Further experiments for prion detection were conducted in 20 times 
diluted baby formula. Table (7) explains the undesirable effect of baby formula 
on the differences between control and antibody samples of baby formula. 
Differences between buffer control and antibody samples were 47% as 
compared to 3% for the baby formula samples.  
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Figure 28: Influence of baby formula dilution on the decoy peak. Decoy peak was at 514 nm 
 and baby formula has a broad peak at 526-528 nm. 
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Figure 29: Decoy linear range study in 20 times diluted baby formula. R2 value is 0.995.  
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Table 7: 
 Effect of baby formula on the percentage differences between control and antibody  
samples. Baby formula concentration was 1.31 mg/ml.  Data Analysis (Appendix A-19). 
 
Samples Intensity (Counts/sec) Differences in 
Intensity 
Control 335180.00 - 
Control 321684.00 - 
Control 319093.00 - 
Antibody 480693.00 43.41% 
Antibody 481046.00 49.53% 
Antibody 481383.00 50.85% 
Baby formula control 831730.00 - 
Baby formula control 845225.00 - 
Baby formula control 847816.00 - 
Baby formula antibody 860400.00 3.44% 
Baby formula antibody 869829.00 2.91% 
Baby formula antibody 878898.00 3.66% 
 
 
Control = Buffer + Decoy, Antibody = Buffer + Antibody + decoy, Baby formula control = 
 Buffer + Decoy + Baby formula, Baby formula antibody = Buffer + Decoy + Antibody  
+ Baby formula 
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The 3% difference between baby formula control and antibody samples 
were within experimental error of the system therefore cannot be considered 
significantly different. A possible explanation behind this behavior of baby 
formula samples could be that the baby formula is binding with the decoy due to 
formula’s sticky nature, and enough free decoy is not available for the antibody 
to bind. It had been cited in the literature that milk solids and proteins are used 
to reduce the nonspecific binding in antibody-antigen reactions (Kaur et al., 
2002). The ability of milk powder to stick with the molecules serves as a good 
blocking agent in antibody-antigen reactions.  
To reduce the possible interactions of baby formula with the decoy, a 
small amount (0.454 mg/ml) of Triton-X (detergent) was added to the baby 
formula samples. Addition of Triton-X improved the differences between the 
baby formula control and the baby formula antibody sample. Table (8) explains 
the effect of Triton-X on the baby formula samples. Percentage differences 
between control and antibody samples were similar for the buffer and the baby 
formula samples. The average percentage difference for buffer samples was 
17.35 and for baby formula samples 16.12. Concentration of baby formula has 
an adverse effect on the intensity differences between control and antibody 
samples. 
 As the concentration of baby formula increased from 1.31 mg/ml to 9.17 
mg/ml the differences between the samples decreased from 15.59% to 8.25% 
Figure (30 & 31). Hence, the concentrations more than 9.17 mg/ml of baby  
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 Table 8: 
 Effect of Triton-X-100 on the % differences in baby formula control and antibody  
samples. Decoy concentration 10 nM, antibody concentration10 nM, Triton-X-100  
0.454 [mg/ml] and baby formula concentration is 1.31 mg/ml. Data analysis 
 (Appendix A-20). 
Sample Average Intensity 
(Counts/sec) 
% Difference in 
intensity 
Control 327150.67 - 
Antibody sample 383919.00 17.35 
Baby formula control 477219.67 - 
Baby formula antibody 471367.67 -1.23 
Baby formula Triton control 482852.67 - 
Baby formula Triton 
antibody 
560683.33 16.12 
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Figure 30: Effect of baby formula concentration on the % differences in the intensity  
Baby formula concentration [mg/ml]
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of control and antibody samples. Decoy concentration 10 nM, antibody concentration 
10 nM, Triton-X –100 0.454 [mg/ml].  Data analysis (Appendix A-21). 
Ab*- Antibody 
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Figure 31: Scans of baby formula control and antibody samples at different  
concentrations. 
BFC- Baby formula control, BFAb- Baby formula antibody sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84
 
Prion Concentration [nM]
0 5 10 15 20 25
In
te
ns
ity
 R
at
io
 *o
f P
rio
n 
to
 n
o 
Pr
io
n 
sa
m
pl
e
1.00
1.05
1.10
1.15
1.20
1.25
1.30
1.35
 
Figure 32: Prion detection curve in 1.31 mg/ml baby formula. Decoy concentration  
was 10 nM, antibody concentration was 10 nM. Prion was added in the increasing  
ratio to decoy, Triton-X was 0.454 mg/ml. Data analysis (Appendix A-22). 
Intensity Ratio* is defined as the ratio of mean fluorescence intensities of prion  
samples to the no prion sample/antibody sample. 
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formula may result in very small differences between control and antibody 
samples, which may not be statistically significant. Figure (32) represents the 
prion detection curve in 1.31 mg/ml baby formula. The minimum detectable 
concentration of prion from no prion sample was 2 nM. All the prion 
concentrations were significantly different at p<0.05 from each other. Figure (33) 
represents the prion detection curve in 5.34 mg/ml baby formula solution. The 
lowest detectable prion concentration was 2 nM that is similar to the prion 
detection curve at 1.31 mg/ml baby formula concentration. All the prion 
concentrations except 10 and 15 nM were significantly different from each other 
at p<0.05. No difference between 10 and 15 nM prion samples can be attributed 
to experimental uncertainties. It can be ascertained that the developed bio-
sensing technique can be used to detect prion in baby formula samples Figure 
(32&33). Addition of Triton-X-100 reduces non-specific interactions between the 
baby formula and decoy. The lowest detectable prion concentration was 2 nM. 
5.7 Effect of Prion and Detergents on Decoy Fluorescence 
 As the concentration of prion increased, fluorescence intensity of the 
samples approached that of the control value. Experiments were done to 
establish that the change in the intensity of prion samples was due to the 
proposed displacement of the decoy by the prion. Table (9) shows the effect of 
different prion concentrations on the decoy fluorescence. The difference among 
the samples were not significant at p<0.05. Therefore, it can be said that 
addition of  
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Figure 33: Prion detection curve in 5.34 mg/ml baby formula. Decoy concentration  
was 10 nM, antibody concentration was 10 nM. Prion was added in the increasing  
ratio to decoy, Triton-X was 0.454 mg/ml. Data analysis (Appendix A-23). 
Intensity ratio* is defined as ratio of mean fluorescence intensities of prion samples 
 to the no prion sample/antibody sample. 
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Table 9: 
Effect of prion concentration on decoy fluorescence. Decoy concentration was 4  
nM and experiment was done in Phosphate buffer. Data Analysis (Appendix A-24). 
 
Prion Concentration [nM] Average Intensity Values 
(counts/sec) 
0 140825.00 
0.5 143357.00 
0.8 134954.00 
1.0 143475.00 
2.0 147381.00 
5.0 143266.00 
10.0 144110.00 
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prion does not change the decoy fluorescence and that change in the intensity of 
the prion samples was due to the displacement reaction. 
Similar experiments were done to ascertain that detergents like SDS and 
Triton-X do not have any significant influence on the fluorescence of decoy.  
Results are shown in Table (10) and Figure (34 & 35); Fluorescence intensity of 
the decoy only in phosphate buffer was not significantly different from the 
solutions containing decoy and detergents like SDS and Triton-X. Figure (34) 
represents the scan of phosphate buffer, SDS and Triton-X. SDS and Triton-X 
solution were made in phosphate buffer only.  
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Table 10: 
 Effect of SDS and Triton-X on the decoy fluorescence. Decoy concentration was 10 nM. 
 Data analysis (Appendix A-25). 
 
 
 
 
 
 
Decoy 
Concentration 
[nM] 
Buffer and Decoy-
Intensities 
(Counts/sec) 
Buffer SDS and 
decoy- Intensities 
(Counts/sec) 
Buffer Triton 
and decoy -
Intensities 
(Counts/sec) 
10 359893.00 360993.00 339610.00 
10 330187.00 369390.00 331484.00 
10 361084.00 367008.00 349127.00 
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Figure 34: Effect of detergents on decoy fluorescence. 
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Figure 35: Scans of buffer, SDS and Triton-X-100. 
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CHAPTER VI 
CONCLUSIONS AND RECOMMENDATIONS 
6.1 Summary of All the Results 
 An affinity-based biosensor was developed to detect prions (causative 
agent for mad cow disease). Initial experimental conditions were established in 
0.1M sodium phosphate buffer. The time for the antibody decoy reaction to 
reach equilibrium was less than four hours. The optimum pH for the reaction was 
7±0.01 and decoy was displaced by prion in less than four hours. The incubation 
temperature of the samples was room temperature (25±5°C) and the samples 
were covered in aluminum foil to prevent photo bleaching.  
Once the experimental conditions for the buffer system were defined 
implementation of the technique was done in food systems like gelatin and baby 
formula. Detergents like SDS and Triton-X blocked the non-specific interactions 
of the gelatin and the baby formula with the decoy. Prion detection curves were 
generated in gelatin and baby formula. The lowest detectable concentration was 
0.5 nM in gelatin and 2 nM in the case of baby formula. 
The results obtained from all the experiments can be summarized as: 
The decoy fluorescence was pH dependent. As the pH of the buffer was 
increased, the fluorescence intensity increased to a maximum value. 
The fluorescence of the dye changed with the polarity of the solvent. The 
intensity increased in more polar solvents. 
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The reaction between the antibody and the decoy reached equilibrium in less 
than four hours. The optimum pH for the reaction was 7 because the 
maximum difference between the control and the antibody sample was 
observed at pH 7. Upon binding with the antibody, the decoy fluorescence 
increased (15-60%) as compared to the control sample. 
High prion concentration control samples (60 nM onwards) showed an 
increase in the fluorescence intensity due to possible aggregation of prion in 
the final samples.  
The prion displaced the bound decoy in less than four hours. All the prion 
samples incubated for four hours showed no unusual increase in the 
fluorescence intensity. Therefore the equilibrium time for the reaction was 
less than four hours. 
The sensitivity of the biosensor was high for the low concentrations (less 
than 20 nM) of antibody and decoy. At high concentrations, saturation effect 
was observed. The equilibrium constant for the reaction was close to 1*109 
mole-1
The lowest detectable prion concentration in phosphate buffer at 4 nM decoy 
concentration was 8 nM. In the case of 1 nM decoy concentration, it was 
close to 0.5 nM. 
At 1 nM decoy concentration, quenching between control and antibody 
samples was observed. A possible explanation could be that binding of one 
decoy molecule to the antibody changes the affinity of the antibody for the 
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second decoy molecule and leads to a different binding model. It is possible 
that the 1nM samples need more incubation time to reach equilibrium. 
Gelatin reduced the differences between control and antibody samples due 
to some non-specific binding.  
The addition of SDS to the gelatin samples improved the differences 
between control and antibody samples. The minimum detectable prion 
concentration in gelatin samples was 0.5 nM.  
The sensitivity of the detection decreased as the concentration of gelatin was 
increased. At 0.4 mg/ml it was 0.5 nM and 2 nM at 2 mg/ml. 
Full strength baby formula has an intrinsic fluorescence peak at 526 nm. The 
strength of the baby formula affects the decoy fluorescence and the decoy 
peak decreased as the strength of the baby formula was increased. 
Dilution of baby formula by twenty times produced a linear curve of decoy 
concentration and intensity with R2 of 0.995. Dilutions higher than 20 times 
gave even better linear relationship. 
The difference in the intensities of the control and antibody samples 
decreased in the presence of baby formula. Addition of Triton-X 100 
(detergent) improved the differences between the control and antibody 
samples of baby formula. 
The prion detection limit in 1.31 mg/ml and 5.34 mg/ml baby formula samples 
was between 2 to 20 nM respectively. 
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6.2 Specific Inferences 
 On the basis of the data obtained from the different experiments 
following inferences can be drawn: 
Present detection technique can be used to detect prion in the buffer, gelatin 
and the baby formula. 
Detection limit of the sensing technique was 8 nM in the case of buffer, 0.5 nM in 
the 0.4 mg/ml gelatin and 2 nM in the baby formula at 1.31 and 5.34 mg/ml 
concentrations. 
Addition of ionic and non-ionic surfactants like SDS and Triton-X-100 facilitated 
the prion detection in the foods by reducing the non-specific binding. 
High concentrations of the gelatin and the baby formula adversely affected the 
detection limit and sensing abilities of the biosensor. 
 
6.3 Recommendations 
On the basis of experimental data it can be concluded that the proposed 
bio-sensing technique can be used to detect prion in gelatin and baby formula 
samples. Detection limit of the biosensor is in the low nano molar range but still 
not equivalent to other detection techniques like ELISA and Western Blot. 
Although the present bio-sensing scheme is the most novel method of 
sensing prion in foods, it requires certain modifications. How to improve the 
sensitivity of the bio sensor in low pico molar range, how to predict interactions 
of foods materials containing meat with antibody, decoy, or prion, and how to 
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establish a scientific hypothesis to explain odd behavior exhibited by food 
materials are some questions which need to be further investigated. 
In the present research work, only non-infectious prion was detected 
using the proposed biosensor. Experiments involving infectious prion have not 
been done. However the present detection technique can be used to detect 
infectious prion using the fact that infectious prion has resistance to enzymes 
like Proteases. Therefore by modifying the sample preparation (pretreatment of 
the prion samples with Proteases) procedure biosensor can be used to 
differentiate between non-infectious prion from the infectious prion. 
Another important aspect that has not been addressed in this research is 
how to extend the use of the present technique to detect BSE in live animals. A 
possible way would be to test the blood or cellular fluids of animals to sense the 
presence of prion. 
In conclusion, it can be said that the proposed bio-sensing strategy can 
be used to detect prions in buffer as well as foods. There are certain questions 
like sensitivity, detection limits, extending use of technique to detect infectious 
prion in foods and live animals need to be addressed. The current biosensor can 
be used as a platform to design a more robust and sensitive sensor to detect 
BSE in foods and live animals. 
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TableA-1: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
pH studies of fluorescein. 
Descriptives
INTENSIT
3 6573.6800 460.46737 265.85096 5429.8156 7717.5444
3 48051.67 827.25785 477.61754 45996.6443 50106.6891
3 69380.53 762.32935 440.13106 67486.8022 71274.2644
3 97988.97 1441.11781 832.02976 94409.0316 101568.9018
3 102923.7 2175.24535 1255.878 97520.0577 108327.2757
3 54343.07 1380.59026 797.08416 50913.4903 57772.6430
18 63210.26 33469.10522 7888.744 46566.4689 79854.0578
5.00
6.00
7.00
8.00
9.00
10.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
INTENSIT
1.90E+10 5 3804538586 2239.704 .000
20384148 12 1698679.021
1.90E+10 17
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-41477.987* 1064.168 .000 -43796.6087 -39159.3646
-62806.853* 1064.168 .000 -65125.4754 -60488.2313
-91415.287* 1064.168 .000 -93733.9087 -89096.6646
-96349.987* 1064.168 .000 -98668.6087 -94031.3646
-47769.387* 1064.168 .000 -50088.0087 -45450.7646
41477.9867* 1064.168 .000 39159.3646 43796.6087
-21328.867* 1064.168 .000 -23647.4887 -19010.2446
-49937.300* 1064.168 .000 -52255.9220 -47618.6780
-54872.000* 1064.168 .000 -57190.6220 -52553.3780
-6291.4000* 1064.168 .000 -8610.0220 -3972.7780
62806.8533* 1064.168 .000 60488.2313 65125.4754
21328.8667* 1064.168 .000 19010.2446 23647.4887
-28608.433* 1064.168 .000 -30927.0554 -26289.8113
-33543.133* 1064.168 .000 -35861.7554 -31224.5113
15037.4667* 1064.168 .000 12718.8446 17356.0887
91415.2867* 1064.168 .000 89096.6646 93733.9087
49937.3000* 1064.168 .000 47618.6780 52255.9220
28608.4333* 1064.168 .000 26289.8113 30927.0554
-4934.7000* 1064.168 .001 -7253.3220 -2616.0780
43645.9000* 1064.168 .000 41327.2780 45964.5220
96349.9867* 1064.168 .000 94031.3646 98668.6087
54872.0000* 1064.168 .000 52553.3780 57190.6220
33543.1333* 1064.168 .000 31224.5113 35861.7554
4934.7000* 1064.168 .001 2616.0780 7253.3220
48580.6000* 1064.168 .000 46261.9780 50899.2220
47769.3867* 1064.168 .000 45450.7646 50088.0087
6291.4000* 1064.168 .000 3972.7780 8610.0220
-15037.467* 1064.168 .000 -17356.0887 -12718.8446
-43645.900* 1064.168 .000 -45964.5220 -41327.2780
-48580.600* 1064.168 .000 -50899.2220 -46261.9780
(J) PH
6.00
7.00
8.00
9.00
10.00
5.00
7.00
8.00
9.00
10.00
5.00
6.00
8.00
9.00
10.00
5.00
6.00
7.00
9.00
10.00
5.00
6.00
7.00
8.00
10.00
5.00
6.00
7.00
8.00
9.00
(I) PH
5.00
6.00
7.00
8.00
9.00
10.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-2: Descriptive Statistics, ANOVA and mean comparison (LSD) to 
see the effect of solvent on decoy fluorescence. 
Descriptives
INTENSIT
3 69380.53 762.32935 440.13106 67486.8022 71274.2644
3 21710.70 251.86558 145.41466 21085.0312 22336.3688
3 72772.07 1059.17889 611.51722 70140.9204 75403.2129
9 54621.10 24735.37841 8245.126 35607.8050 73634.3950
1.00
2.00
3.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
INTENSIT
4.89E+09 2 2445589337 4153.415 .000
3532884 6 588814.079
4.89E+09 8
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
47669.8333* 626.53230 .000 46136.7640 49202.9026
-3391.5333* 626.53230 .002 -4924.6026 -1858.4640
-47669.833* 626.53230 .000 -49202.9026 -46136.7640
-51061.367* 626.53230 .000 -52594.4360 -49528.2974
3391.5333* 626.53230 .002 1858.4640 4924.6026
51061.3667* 626.53230 .000 49528.2974 52594.4360
(J) TRT
2.00
3.00
1.00
3.00
1.00
2.00
(I) TRT
1.00
2.00
3.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-3: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
binding studies at different pH values. 
Descriptives
DIFFEREN
3 9.4033 .59652 .34440 7.9215 10.8852
3 41.0300 2.17580 1.25620 35.6250 46.4350
3 27.7200 1.66934 .96379 23.5731 31.8669
9 26.0511 13.82324 4.60775 15.4256 36.6766
6.00
7.00
8.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
DIFFEREN
1512.902 2 756.451 288.112 .000
15.753 6 2.626
1528.656 8
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: DIFFEREN
LSD
-31.6267* 1.32301 .000 -34.8640 -28.3894
-18.3167* 1.32301 .000 -21.5540 -15.0794
31.6267* 1.32301 .000 28.3894 34.8640
13.3100* 1.32301 .000 10.0727 16.5473
18.3167* 1.32301 .000 15.0794 21.5540
-13.3100* 1.32301 .000 -16.5473 -10.0727
(J) PH
7.00
8.00
6.00
8.00
6.00
7.00
(I) PH
6.00
7.00
8.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-4: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
equilibrium study for antibody antigen reaction. 
 
 
Descriptives
VAR00003
3 16.9733 6.29712 3.63564 1.3304 32.6162
3 29.6800 1.66529 .96146 25.5432 33.8168
3 20.0233 4.59970 2.65564 8.5970 31.4496
3 29.3200 4.10004 2.36716 19.1349 39.5051
3 17.8433 2.88084 1.66325 10.6869 24.9997
3 20.5633 7.08001 4.08765 2.9756 38.1511
3 18.8433 1.98651 1.14691 13.9086 23.7781
21 21.8924 6.31834 1.37877 19.0163 24.7685
.00
1.00
2.00
4.00
5.00
10.00
20.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
 
ANOVA
VAR00003
512.894 6 85.482 4.191 .013
285.533 14 20.395
798.427 20
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-12.7067* 3.43887 .004 -20.3689 -5.0444
-3.0500 3.43887 .396 -10.7123 4.6123
-12.3467* 3.43887 .005 -20.0089 -4.6844
-.8700 3.43887 .805 -8.5323 6.7923
12.7067* 3.43887 .004 5.0444 20.3689
9.6567* 3.43887 .019 1.9944 17.3189
.3600 3.43887 .919 -7.3023 8.0223
11.8367* 3.43887 .006 4.1744 19.4989
3.0500 3.43887 .396 -4.6123 10.7123
-9.6567* 3.43887 .019 -17.3189 -1.9944
-9.2967* 3.43887 .022 -16.9589 -1.6344
2.1800 3.43887 .540 -5.4823 9.8423
12.3467* 3.43887 .005 4.6844 20.0089
-.3600 3.43887 .919 -8.0223 7.3023
9.2967* 3.43887 .022 1.6344 16.9589
11.4767* 3.43887 .008 3.8144 19.1389
.8700 3.43887 .805 -6.7923 8.5323
-11.8367* 3.43887 .006 -19.4989 -4.1744
-2.1800 3.43887 .540 -9.8423 5.4823
-11.4767* 3.43887 .008 -19.1389 -3.8144
(J) VAR00001
1.00
2.00
4.00
5.00
.00
2.00
4.00
5.00
.00
1.00
4.00
5.00
.00
1.00
2.00
5.00
.00
1.00
2.00
4.00
(I) VAR00001
.00
1.00
2.00
4.00
5.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-5: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
BSA and antibody studies. 
 
Descriptives
DIFF
3 .0000 .00000 .00000 .0000 .0000
3 56.8667 6.50125 3.75350 40.7167 73.0167
3 .3800 7.77699 4.49005 -18.9391 19.6991
9 19.0822 28.78846 9.59615 -3.0465 41.2110
1
2
3
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
DIFF
6424.706 2 3212.353 93.793 .000
205.496 6 34.249
6630.201 8
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: DIFF
LSD
-56.8667* 4.77837 .000 -68.5589 -45.1744
-.3800 4.77837 .939 -12.0723 11.3123
56.8667* 4.77837 .000 45.1744 68.5589
56.4867* 4.77837 .000 44.7944 68.1789
.3800 4.77837 .939 -11.3123 12.0723
-56.4867* 4.77837 .000 -68.1789 -44.7944
(J) SAMPLE
2
3
1
3
1
2
(I) SAMPLE
1
2
3
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-6: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the antibody affinity study. 
Descriptives
INTENSIT
3 57090.29 2621.71755 1513.649 50577.5792 63602.9941
3 79998.70 1316.13773 759.87247 76729.2326 83268.1674
3 91191.57 312.66623 180.51793 90414.8607 91968.2726
3 92632.30 531.03593 306.59374 91313.1336 93951.4664
3 92060.47 276.36355 159.55857 91373.9415 92746.9918
3 89517.93 1151.78891 664.98564 86656.7311 92379.1356
3 93775.27 1486.77292 858.38874 90081.9180 97468.6153
3 108602.1 6172.70673 3563.814 93268.2131 123935.9202
3 112862.7 3601.26663 2079.192 103916.6244 121808.7089
3 112353.0 3873.22243 2236.206 102731.3821 121974.6179
30 93008.43 16211.39927 2959.783 86954.9894 99061.8613
.00
1.00
2.00
4.00
5.00
8.00
20.00
55.00
88.00
110.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
7.46E+09 9 829347802.6 105.418 .000
1.57E+08 20 7867215.075
7.62E+09 29
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Table A-7: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
Prion aggregation study. 
 
Descriptives
INTENSIT
3 63613.30 1900.40455 1097.199 58892.4334 68334.1666
3 56912.20 1864.17814 1076.284 52281.3248 61543.0752
3 74020.00 4091.10803 2362.002 63857.1243 84182.8757
3 81498.63 664.48386 383.63994 79847.9639 83149.3028
3 108978.7 4565.12095 2635.674 97638.2775 120319.0558
15 77004.56 18886.20274 4876.397 66545.7295 87463.3905
.00
10.00
20.00
60.00
90.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
4.90E+09 4 1225857424 135.887 .000
90211461 10 9021146.125
4.99E+09 14
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
6701.1000* 2452.366 .021 1236.8888 12165.3112
-10406.700* 2452.366 .002 -15870.9112 -4942.4888
-17885.333* 2452.366 .000 -23349.5446 -12421.1221
-45365.367* 2452.366 .000 -50829.5779 -39901.1554
-6701.1000* 2452.366 .021 -12165.3112 -1236.8888
-17107.800* 2452.366 .000 -22572.0112 -11643.5888
-24586.433* 2452.366 .000 -30050.6446 -19122.2221
-52066.467* 2452.366 .000 -57530.6779 -46602.2554
10406.7000* 2452.366 .002 4942.4888 15870.9112
17107.8000* 2452.366 .000 11643.5888 22572.0112
-7478.6333* 2452.366 .012 -12942.8446 -2014.4221
-34958.667* 2452.366 .000 -40422.8779 -29494.4554
17885.3333* 2452.366 .000 12421.1221 23349.5446
24586.4333* 2452.366 .000 19122.2221 30050.6446
7478.6333* 2452.366 .012 2014.4221 12942.8446
-27480.033* 2452.366 .000 -32944.2446 -22015.8221
45365.3667* 2452.366 .000 39901.1554 50829.5779
52066.4667* 2452.366 .000 46602.2554 57530.6779
34958.6667* 2452.366 .000 29494.4554 40422.8779
27480.0333* 2452.366 .000 22015.8221 32944.2446
(J) PRIONCON
10.00
20.00
60.00
90.00
.00
20.00
60.00
90.00
.00
10.00
60.00
90.00
.00
10.00
20.00
90.00
.00
10.00
20.00
60.00
(I) PRIONCON
.00
10.00
20.00
60.00
90.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-8: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
Prion aggregation in control. 
Descriptives
INTENSIT
3 40132.73 321.99612 185.90455 39332.8506 40932.6160
3 43974.30 1976.59573 1141.188 39064.1640 48884.4360
3 45185.03 1022.05780 590.08535 42646.1010 47723.9657
3 49166.63 1756.37711 1014.045 44803.5507 53529.7159
3 68122.73 2191.94836 1265.522 62677.6317 73567.8349
15 49316.29 10270.72506 2651.890 43628.5487 55004.0246
.00
10.00
20.00
60.00
90.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
ANOVA
INTENSIT
1.45E+09 4 362734919.9 140.109 .000
25889425 10 2588942.497
1.48E+09 14
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119
 
 
Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-3841.5667* 1313.759 .015 -6768.8033 -914.3301
-5052.3000* 1313.759 .003 -7979.5366 -2125.0634
-9033.9000* 1313.759 .000 -11961.1366 -6106.6634
-27990.000* 1313.759 .000 -30917.2366 -25062.7634
3841.5667* 1313.759 .015 914.3301 6768.8033
-1210.7333 1313.759 .378 -4137.9699 1716.5033
-5192.3333* 1313.759 .003 -8119.5699 -2265.0967
-24148.433* 1313.759 .000 -27075.6699 -21221.1967
5052.3000* 1313.759 .003 2125.0634 7979.5366
1210.7333 1313.759 .378 -1716.5033 4137.9699
-3981.6000* 1313.759 .013 -6908.8366 -1054.3634
-22937.700* 1313.759 .000 -25864.9366 -20010.4634
9033.9000* 1313.759 .000 6106.6634 11961.1366
5192.3333* 1313.759 .003 2265.0967 8119.5699
3981.6000* 1313.759 .013 1054.3634 6908.8366
-18956.100* 1313.759 .000 -21883.3366 -16028.8634
27990.0000* 1313.759 .000 25062.7634 30917.2366
24148.4333* 1313.759 .000 21221.1967 27075.6699
22937.7000* 1313.759 .000 20010.4634 25864.9366
18956.1000* 1313.759 .000 16028.8634 21883.3366
(J) PRPCONC
10.00
20.00
60.00
90.00
.00
20.00
60.00
90.00
.00
10.00
60.00
90.00
.00
10.00
20.00
90.00
.00
10.00
20.00
60.00
(I) PRPCONC
.00
10.00
20.00
60.00
90.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-9: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
Prion kinetic study. 
Descriptives
DIFFEREN
3 -14.7800 13.26193 7.65678 -47.7245 18.1645
3 -20.3467 1.98782 1.14767 -25.2847 -15.4086
3 -34.3600 3.42969 1.98013 -42.8798 -25.8402
3 -32.2233 25.02059 14.44565 -94.3779 29.9313
12 -25.4275 14.86520 4.29121 -34.8724 -15.9826
.00
2.00
4.00
11.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
DIFFEREN
795.471 3 265.157 1.297 .340
1635.246 8 204.406
2430.717 11
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: DIFFEREN
LSD
5.5667 11.67350 .646 -21.3525 32.4858
19.5800 11.67350 .132 -7.3391 46.4991
17.4433 11.67350 .173 -9.4758 44.3625
-5.5667 11.67350 .646 -32.4858 21.3525
14.0133 11.67350 .264 -12.9058 40.9325
11.8767 11.67350 .339 -15.0425 38.7958
-19.5800 11.67350 .132 -46.4991 7.3391
-14.0133 11.67350 .264 -40.9325 12.9058
-2.1367 11.67350 .859 -29.0558 24.7825
-17.4433 11.67350 .173 -44.3625 9.4758
-11.8767 11.67350 .339 -38.7958 15.0425
2.1367 11.67350 .859 -24.7825 29.0558
(J) TIME
2.00
4.00
11.00
.00
4.00
11.00
.00
2.00
11.00
.00
2.00
4.00
(I) TIME
.00
2.00
4.00
11.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122
Table A-10: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement study in phosphate buffer at 4nM decoy. 
Descriptives
INTENSIT
3 61918.43 703.61677 406.23333 60170.5524 63666.3143
3 60787.40 831.05742 479.81123 58722.9389 62851.8611
3 61678.77 1156.81669 667.88843 58805.0747 64552.4586
3 56828.17 662.76922 382.64999 55181.7566 58474.5767
3 54444.47 158.67143 91.60899 54050.3050 54838.6284
3 53203.53 119.75451 69.14030 52906.0466 53501.0200
3 52414.43 675.52506 390.01457 50736.3361 54092.5306
21 57325.03 3949.56284 861.86527 55527.2091 59122.8480
.00
2.00
4.00
8.00
10.00
20.00
40.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
3.05E+08 6 50843797.92 102.891 .000
6918146 14 494153.254
3.12E+08 20
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: VAR00002
LSD
1131.0333 577.61374 .074 -127.4789 2389.5456
239.6667 577.61374 .686 -1018.8456 1498.1789
5090.2667* 577.61374 .000 3831.7544 6348.7789
7473.9667* 577.61374 .000 6215.4544 8732.4789
8714.9000* 577.61374 .000 7456.3878 9973.4122
-1131.0333 577.61374 .074 -2389.5456 127.4789
-891.3667 577.61374 .149 -2149.8789 367.1456
3959.2333* 577.61374 .000 2700.7211 5217.7456
6342.9333* 577.61374 .000 5084.4211 7601.4456
7583.8667* 577.61374 .000 6325.3544 8842.3789
-239.6667 577.61374 .686 -1498.1789 1018.8456
891.3667 577.61374 .149 -367.1456 2149.8789
4850.6000* 577.61374 .000 3592.0878 6109.1122
7234.3000* 577.61374 .000 5975.7878 8492.8122
8475.2333* 577.61374 .000 7216.7211 9733.7456
-5090.2667* 577.61374 .000 -6348.7789 -3831.7544
-3959.2333* 577.61374 .000 -5217.7456 -2700.7211
-4850.6000* 577.61374 .000 -6109.1122 -3592.0878
2383.7000* 577.61374 .001 1125.1878 3642.2122
3624.6333* 577.61374 .000 2366.1211 4883.1456
-7473.9667* 577.61374 .000 -8732.4789 -6215.4544
-6342.9333* 577.61374 .000 -7601.4456 -5084.4211
-7234.3000* 577.61374 .000 -8492.8122 -5975.7878
-2383.7000* 577.61374 .001 -3642.2122 -1125.1878
1240.9333 577.61374 .053 -17.5789 2499.4456
-8714.9000* 577.61374 .000 -9973.4122 -7456.3878
-7583.8667* 577.61374 .000 -8842.3789 -6325.3544
-8475.2333* 577.61374 .000 -9733.7456 -7216.7211
-3624.6333* 577.61374 .000 -4883.1456 -2366.1211
-1240.9333 577.61374 .053 -2499.4456 17.5789
(J) VAR00001
2.00
4.00
8.00
10.00
20.00
.00
4.00
8.00
10.00
20.00
.00
2.00
8.00
10.00
20.00
.00
2.00
4.00
10.00
20.00
.00
2.00
4.00
8.00
20.00
.00
2.00
4.00
8.00
10.00
(I) VAR00001
.00
2.00
4.00
8.00
10.00
20.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-11: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement study in phosphate buffer at 1nM decoy. 
Descriptives
INTENSIT
3 31216.37 933.38297 538.88891 28897.7148 33535.0185
3 23049.57 587.19234 339.01566 21590.9000 24508.2333
3 28219.87 530.30604 306.17233 26902.5134 29537.2199
3 29719.40 1381.86269 797.81880 26286.6628 33152.1372
3 34708.27 402.27107 232.25131 33708.9699 35707.5634
3 31926.73 211.87006 122.32324 31400.4189 32453.0477
3 47069.70 291.85097 168.50024 46344.7020 47794.6980
3 50160.63 1108.77378 640.15084 47406.2866 52914.9801
24 34508.82 8973.81326 1831.772 30719.5077 38298.1257
.00
.20
.50
1.00
2.00
5.00
8.00
10.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
INTENSIT
1.84E+09 7 263188342.0 427.251 .000
9856070 16 616004.353
1.85E+09 23
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
8166.8000* 689.79124 .000 6629.8493 9703.7507
2996.5000* 689.79124 .001 1459.5493 4533.4507
1496.9667 689.79124 .055 -39.9840 3033.9173
-3491.9000* 689.79124 .000 -5028.8507 -1954.9493
-8166.8000* 689.79124 .000 -9703.7507 -6629.8493
-5170.3000* 689.79124 .000 -6707.2507 -3633.3493
-6669.8333* 689.79124 .000 -8206.7840 -5132.8827
-11658.700* 689.79124 .000 -13195.6507 -10121.7493
-2996.5000* 689.79124 .001 -4533.4507 -1459.5493
5170.3000* 689.79124 .000 3633.3493 6707.2507
-1499.5333 689.79124 .055 -3036.4840 37.4173
-6488.4000* 689.79124 .000 -8025.3507 -4951.4493
-1496.9667 689.79124 .055 -3033.9173 39.9840
6669.8333* 689.79124 .000 5132.8827 8206.7840
1499.5333 689.79124 .055 -37.4173 3036.4840
-4988.8667* 689.79124 .000 -6525.8173 -3451.9160
3491.9000* 689.79124 .000 1954.9493 5028.8507
11658.7000* 689.79124 .000 10121.7493 13195.6507
6488.4000* 689.79124 .000 4951.4493 8025.3507
4988.8667* 689.79124 .000 3451.9160 6525.8173
(J) VAR00001
.20
.50
1.00
2.00
.00
.50
1.00
2.00
.00
.20
1.00
2.00
.00
.20
.50
2.00
.00
.20
.50
1.00
(I) VAR00001
.00
.20
.50
1.00
2.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-15142.967* 549.63527 .000 -16487.8757 -13798.0576
-18233.900* 549.63527 .000 -19578.8091 -16888.9909
15142.9667* 549.63527 .000 13798.0576 16487.8757
-3090.9333* 549.63527 .001 -4435.8424 -1746.0243
18233.9000* 549.63527 .000 16888.9909 19578.8091
3090.9333* 549.63527 .001 1746.0243 4435.8424
(J) VAR00003
8.00
10.00
5.00
10.00
5.00
8.00
(I) VAR00003
5.00
8.00
10.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-12: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement study in 0.01mg/ml gelatin at 4nM decoy. 
Descriptives
INTENSIT
3 47311.20 697.25280 402.55909 45579.1280 49043.2720
3 44868.90 2865.57834 1654.442 37750.4088 51987.3912
3 43086.17 1245.39746 719.03056 39992.4279 46179.9055
3 44268.33 1059.51710 611.71249 41636.3469 46900.3197
3 40872.40 808.26129 466.64987 38864.5677 42880.2323
15 44081.40 2551.94314 658.90889 42668.1810 45494.6190
.00
2.00
4.00
8.00
10.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
INTENSIT
67124636 4 16781159.06 6.978 .006
24049157 10 2404915.669
91173793 14
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
2442.3000 1266.206 .083 -378.9823 5263.5823
4225.0333* 1266.206 .008 1403.7510 7046.3157
3042.8667* 1266.206 .037 221.5843 5864.1490
6438.8000* 1266.206 .000 3617.5177 9260.0823
-2442.3000 1266.206 .083 -5263.5823 378.9823
1782.7333 1266.206 .189 -1038.5490 4604.0157
600.5667 1266.206 .645 -2220.7157 3421.8490
3996.5000* 1266.206 .010 1175.2177 6817.7823
-4225.0333* 1266.206 .008 -7046.3157 -1403.7510
-1782.7333 1266.206 .189 -4604.0157 1038.5490
-1182.1667 1266.206 .372 -4003.4490 1639.1157
2213.7667 1266.206 .111 -607.5157 5035.0490
-3042.8667* 1266.206 .037 -5864.1490 -221.5843
-600.5667 1266.206 .645 -3421.8490 2220.7157
1182.1667 1266.206 .372 -1639.1157 4003.4490
3395.9333* 1266.206 .023 574.6510 6217.2157
-6438.8000* 1266.206 .000 -9260.0823 -3617.5177
-3996.5000* 1266.206 .010 -6817.7823 -1175.2177
-2213.7667 1266.206 .111 -5035.0490 607.5157
-3395.9333* 1266.206 .023 -6217.2157 -574.6510
(J) CONC
2.00
4.00
8.00
10.00
.00
4.00
8.00
10.00
.00
2.00
8.00
10.00
.00
2.00
4.00
10.00
.00
2.00
4.00
8.00
(I) CONC
.00
2.00
4.00
8.00
10.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-13: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement study in 0.4mg/ml gelatin at 4nM decoy. 
Descriptives
INTENSIT
3 186319.7 5199.93811 3002.186 173402.3043 199237.0290
3 168287.3 3944.69445 2277.470 158488.1691 178086.4976
3 162936.7 174.50597 100.75107 162503.1698 163370.1635
3 160861.7 3544.86704 2046.630 152055.7288 169667.6046
3 161429.7 3944.74110 2277.497 151630.3865 171228.9468
3 164868.0 466.90577 269.56817 163708.1418 166027.8582
18 167450.5 9493.99088 2237.755 162729.2494 172171.7506
0
2
4
8
10
20
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
1.39E+09 5 278071738.2 23.507 .000
1.42E+08 12 11829248.11
1.53E+09 17
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
 
 
 130
Multiple Comparisons
Dependent Variable: INTENSIT
LSD
18032.3333* 2808.232 .000 11913.7220 24150.9446
23383.0000* 2808.232 .000 17264.3887 29501.6113
25458.0000* 2808.232 .000 19339.3887 31576.6113
24890.0000* 2808.232 .000 18771.3887 31008.6113
21451.6667* 2808.232 .000 15333.0554 27570.2780
-18032.333* 2808.232 .000 -24150.9446 -11913.7220
5350.6667 2808.232 .081 -767.9446 11469.2780
7425.6667* 2808.232 .021 1307.0554 13544.2780
6857.6667* 2808.232 .031 739.0554 12976.2780
3419.3333 2808.232 .247 -2699.2780 9537.9446
-23383.000* 2808.232 .000 -29501.6113 -17264.3887
-5350.6667 2808.232 .081 -11469.2780 767.9446
2075.0000 2808.232 .474 -4043.6113 8193.6113
1507.0000 2808.232 .601 -4611.6113 7625.6113
-1931.3333 2808.232 .505 -8049.9446 4187.2780
-25458.000* 2808.232 .000 -31576.6113 -19339.3887
-7425.6667* 2808.232 .021 -13544.2780 -1307.0554
-2075.0000 2808.232 .474 -8193.6113 4043.6113
-568.0000 2808.232 .843 -6686.6113 5550.6113
-4006.3333 2808.232 .179 -10124.9446 2112.2780
-24890.000* 2808.232 .000 -31008.6113 -18771.3887
-6857.6667* 2808.232 .031 -12976.2780 -739.0554
-1507.0000 2808.232 .601 -7625.6113 4611.6113
568.0000 2808.232 .843 -5550.6113 6686.6113
-3438.3333 2808.232 .244 -9556.9446 2680.2780
-21451.667* 2808.232 .000 -27570.2780 -15333.0554
-3419.3333 2808.232 .247 -9537.9446 2699.2780
1931.3333 2808.232 .505 -4187.2780 8049.9446
4006.3333 2808.232 .179 -2112.2780 10124.9446
3438.3333 2808.232 .244 -2680.2780 9556.9446
(J) PRION
2
4
8
10
20
0
4
8
10
20
0
2
8
10
20
0
2
4
10
20
0
2
4
8
20
0
2
4
8
10
(I) PRION
0
2
4
8
10
20
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-14: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
SDS effect on gelatin samples. 
Descriptives
INTENSIT
3 133127.7 3396.74216 1961.110 124689.6914 141565.6420
3 147980.7 4776.14670 2757.510 136116.0605 159845.2728
3 99916.47 1079.15164 623.04849 97235.7054 102597.2279
3 119617.3 2231.30507 1288.245 114074.4643 125160.2024
12 125160.5 18678.27238 5391.953 113292.9252 137028.1414
1
2
3
4
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
 
ANOVA
INTENSIT
3.76E+09 3 1252223667 123.699 .000
80985451 8 10123181.31
3.84E+09 11
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-14853.000* 2597.843 .000 -20843.6364 -8862.3636
33211.2000* 2597.843 .000 27220.5636 39201.8364
13510.3333* 2597.843 .001 7519.6969 19500.9697
14853.0000* 2597.843 .000 8862.3636 20843.6364
48064.2000* 2597.843 .000 42073.5636 54054.8364
28363.3333* 2597.843 .000 22372.6969 34353.9697
-33211.200* 2597.843 .000 -39201.8364 -27220.5636
-48064.200* 2597.843 .000 -54054.8364 -42073.5636
-19700.867* 2597.843 .000 -25691.5031 -13710.2303
-13510.333* 2597.843 .001 -19500.9697 -7519.6969
-28363.333* 2597.843 .000 -34353.9697 -22372.6969
19700.8667* 2597.843 .000 13710.2303 25691.5031
(J) SAMPLES
2
3
4
1
3
4
1
2
4
1
2
3
(I) SAMPLES
1
2
3
4
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-15: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement in 0.4mg/ml gelatin and 0.3mg/mlSDS samples. 
Descriptives
INTENSIT
3 253162.3 1866.38215 1077.556 248525.9830 257798.6836
3 241309.7 1485.02536 857.37979 237620.6592 244998.6742
3 232625.0 2209.27160 1275.524 227136.8651 238113.1349
3 221545.7 1189.06952 686.50961 218591.8542 224499.4791
3 221991.7 4793.31914 2767.424 210084.4018 233898.9315
3 215263.0 7145.11798 4125.236 197513.5430 233012.4570
18 230982.9 13777.38653 3247.361 224131.5558 237834.2220
.00
.50
.80
1.00
2.00
5.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
3.05E+09 5 610970862.6 42.620 .000
1.72E+08 12 14335344.89
3.23E+09 17
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
11852.6667* 3091.423 .002 5117.0344 18588.2989
20537.3333* 3091.423 .000 13801.7011 27272.9656
31616.6667* 3091.423 .000 24881.0344 38352.2989
31170.6667* 3091.423 .000 24435.0344 37906.2989
37899.3333* 3091.423 .000 31163.7011 44634.9656
-11852.667* 3091.423 .002 -18588.2989 -5117.0344
8684.6667* 3091.423 .016 1949.0344 15420.2989
19764.0000* 3091.423 .000 13028.3678 26499.6322
19318.0000* 3091.423 .000 12582.3678 26053.6322
26046.6667* 3091.423 .000 19311.0344 32782.2989
-20537.333* 3091.423 .000 -27272.9656 -13801.7011
-8684.6667* 3091.423 .016 -15420.2989 -1949.0344
11079.3333* 3091.423 .004 4343.7011 17814.9656
10633.3333* 3091.423 .005 3897.7011 17368.9656
17362.0000* 3091.423 .000 10626.3678 24097.6322
-31616.667* 3091.423 .000 -38352.2989 -24881.0344
-19764.000* 3091.423 .000 -26499.6322 -13028.3678
-11079.333* 3091.423 .004 -17814.9656 -4343.7011
-446.0000 3091.423 .888 -7181.6322 6289.6322
6282.6667 3091.423 .065 -452.9656 13018.2989
-31170.667* 3091.423 .000 -37906.2989 -24435.0344
-19318.000* 3091.423 .000 -26053.6322 -12582.3678
-10633.333* 3091.423 .005 -17368.9656 -3897.7011
446.0000 3091.423 .888 -6289.6322 7181.6322
6728.6667 3091.423 .050 -6.9656 13464.2989
-37899.333* 3091.423 .000 -44634.9656 -31163.7011
-26046.667* 3091.423 .000 -32782.2989 -19311.0344
-17362.000* 3091.423 .000 -24097.6322 -10626.3678
-6282.6667 3091.423 .065 -13018.2989 452.9656
-6728.6667 3091.423 .050 -13464.2989 6.9656
(J) CONC
.50
.80
1.00
2.00
5.00
.00
.80
1.00
2.00
5.00
.00
.50
1.00
2.00
5.00
.00
.50
.80
2.00
5.00
.00
.50
.80
1.00
5.00
.00
.50
.80
1.00
2.00
(I) CONC
.00
.50
.80
1.00
2.00
5.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-16: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement in 1.0mg/ml gelatin and 0.3mg/mlSDS samples. 
Descriptives
INTENSIT
3 129007.7 4103.81400 2369.338 118813.2276 139202.1058
3 125739.0 3212.34167 1854.646 117759.1009 133718.8991
3 124674.3 1890.64019 1091.562 119977.7227 129370.9439
3 117749.3 1334.65738 770.56480 114433.8606 121064.8061
3 113333.3 2214.70931 1278.663 107831.6904 118834.9763
3 106421.0 2061.65152 1190.295 101299.5737 111542.4263
18 119487.4 8359.85731 1970.437 115330.1852 123644.7037
.00
.50
.80
1.00
2.00
5.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
 
ANOVA
INTENSIT
1.10E+09 5 220947887.2 31.813 .000
83343207 12 6945267.222
1.19E+09 17
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
3268.6667 2151.785 .155 -1419.6698 7957.0032
4333.3333 2151.785 .067 -355.0032 9021.6698
11258.3333* 2151.785 .000 6569.9968 15946.6698
15674.3333* 2151.785 .000 10985.9968 20362.6698
22586.6667* 2151.785 .000 17898.3302 27275.0032
-3268.6667 2151.785 .155 -7957.0032 1419.6698
1064.6667 2151.785 .630 -3623.6698 5753.0032
7989.6667* 2151.785 .003 3301.3302 12678.0032
12405.6667* 2151.785 .000 7717.3302 17094.0032
19318.0000* 2151.785 .000 14629.6635 24006.3365
-4333.3333 2151.785 .067 -9021.6698 355.0032
-1064.6667 2151.785 .630 -5753.0032 3623.6698
6925.0000* 2151.785 .007 2236.6635 11613.3365
11341.0000* 2151.785 .000 6652.6635 16029.3365
18253.3333* 2151.785 .000 13564.9968 22941.6698
-11258.333* 2151.785 .000 -15946.6698 -6569.9968
-7989.6667* 2151.785 .003 -12678.0032 -3301.3302
-6925.0000* 2151.785 .007 -11613.3365 -2236.6635
4416.0000 2151.785 .063 -272.3365 9104.3365
11328.3333* 2151.785 .000 6639.9968 16016.6698
-15674.333* 2151.785 .000 -20362.6698 -10985.9968
-12405.667* 2151.785 .000 -17094.0032 -7717.3302
-11341.000* 2151.785 .000 -16029.3365 -6652.6635
-4416.0000 2151.785 .063 -9104.3365 272.3365
6912.3333* 2151.785 .007 2223.9968 11600.6698
-22586.667* 2151.785 .000 -27275.0032 -17898.3302
-19318.000* 2151.785 .000 -24006.3365 -14629.6635
-18253.333* 2151.785 .000 -22941.6698 -13564.9968
-11328.333* 2151.785 .000 -16016.6698 -6639.9968
-6912.3333* 2151.785 .007 -11600.6698 -2223.9968
(J) CONC
.50
.80
1.00
2.00
5.00
.00
.80
1.00
2.00
5.00
.00
.50
1.00
2.00
5.00
.00
.50
.80
2.00
5.00
.00
.50
.80
1.00
5.00
.00
.50
.80
1.00
2.00
(I) CONC
.00
.50
.80
1.00
2.00
5.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
 137
Table A-17: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the effect of antibody concentration on the difference between samples. 
Descriptives
INTENSIT
3 124537.3 2345.05807 1353.920 118711.8862 130362.7805
3 125749.7 3297.45604 1903.787 117558.3318 133941.0016
3 135077.7 2654.08823 1532.339 128484.5460 141670.7873
9 128454.9 5549.92521 1849.975 124188.8387 132720.9391
2.00
3.20
4.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
 
ANOVA
INTENSIT
2.00E+08 2 99789981.44 12.784 .007
46833396 6 7805566.000
2.46E+08 8
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-1212.3333 2281.164 .614 -6794.1413 4369.4747
-10540.333* 2281.164 .004 -16122.1413 -4958.5253
1212.3333 2281.164 .614 -4369.4747 6794.1413
-9328.0000* 2281.164 .006 -14909.8080 -3746.1920
10540.3333* 2281.164 .004 4958.5253 16122.1413
9328.0000* 2281.164 .006 3746.1920 14909.8080
(J) ANTIBODY
3.20
4.00
2.00
4.00
2.00
3.20
(I) ANTIBODY
2.00
3.20
4.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-18: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
decoy displacement in 2.0mg/ml gelatin and 0.3mg/mlSDS samples. 
Descriptives
INTENSIT
3 179525.7 3792.04501 2189.338 170105.7047 188945.6287
3 179253.0 2940.01701 1697.420 171949.5929 186556.4071
3 181544.0 2584.19833 1491.988 175124.4955 187963.5045
3 179146.0 2900.40083 1674.547 171941.0049 186350.9951
3 168460.3 3981.73333 2298.855 158569.1594 178351.5073
3 162681.3 2105.34423 1215.521 157451.3683 167911.2983
18 175101.7 7653.96339 1804.056 171295.4958 178907.9487
.00
.50
.80
1.00
2.00
5.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
8.79E+08 5 5 18.064 .000
1.17E+08 12 12
9.96E+08 17 17
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
272.6667 2547.338 .917 -5277.5064 5822.8398
-2018.3333 2547.338 .444 -7568.5064 3531.8398
379.6667 2547.338 .884 -5170.5064 5929.8398
11065.3333* 2547.338 .001 5515.1602 16615.5064
16844.3333* 2547.338 .000 11294.1602 22394.5064
-272.6667 2547.338 .917 -5822.8398 5277.5064
-2291.0000 2547.338 .386 -7841.1731 3259.1731
107.0000 2547.338 .967 -5443.1731 5657.1731
10792.6667* 2547.338 .001 5242.4936 16342.8398
16571.6667* 2547.338 .000 11021.4936 22121.8398
2018.3333 2547.338 .444 -3531.8398 7568.5064
2291.0000 2547.338 .386 -3259.1731 7841.1731
2398.0000 2547.338 .365 -3152.1731 7948.1731
13083.6667* 2547.338 .000 7533.4936 18633.8398
18862.6667* 2547.338 .000 13312.4936 24412.8398
-379.6667 2547.338 .884 -5929.8398 5170.5064
-107.0000 2547.338 .967 -5657.1731 5443.1731
-2398.0000 2547.338 .365 -7948.1731 3152.1731
10685.6667* 2547.338 .001 5135.4936 16235.8398
16464.6667* 2547.338 .000 10914.4936 22014.8398
-11065.333* 2547.338 .001 -16615.5064 -5515.1602
-10792.667* 2547.338 .001 -16342.8398 -5242.4936
-13083.667* 2547.338 .000 -18633.8398 -7533.4936
-10685.667* 2547.338 .001 -16235.8398 -5135.4936
5779.0000* 2547.338 .043 228.8269 11329.1731
-16844.333* 2547.338 .000 -22394.5064 -11294.1602
-16571.667* 2547.338 .000 -22121.8398 -11021.4936
-18862.667* 2547.338 .000 -24412.8398 -13312.4936
-16464.667* 2547.338 .000 -22014.8398 -10914.4936
-5779.0000* 2547.338 .043 -11329.1731 -228.8269
(J) CONC
.50
.80
1.00
2.00
5.00
.00
.80
1.00
2.00
5.00
.00
.50
1.00
2.00
5.00
.00
.50
.80
2.00
5.00
.00
.50
.80
1.00
5.00
.00
.50
.80
1.00
2.00
(I) CONC
.00
.50
.80
1.00
2.00
5.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-19: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
baby formula control and antibody samples. 
 
Descriptives
INTENSIT
3 325319.0 8637.58132 4986.910 303862.0585 346775.9415
3 481040.7 345.03092 199.20369 480183.5624 481897.7710
3 841590.3 8637.01050 4986.580 820134.8098 863045.8568
3 869709.0 9249.58383 5340.250 846731.7600 892686.2400
12 629414.8 243500.31823 70292.49 474702.0289 784127.4711
1.00
2.00
3.00
4.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
INTENSIT
6.52E+11 3 2.172E+11 3699.749 .000
4.70E+08 8 58719902.17
6.52E+11 11
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-388668.33* 6256.724 .000 -403096.3659 -374240.3008
-360549.67* 6256.724 .000 -374977.6992 -346121.6341
155721.67* 6256.724 .000 141293.6341 170149.6992
388668.33* 6256.724 .000 374240.3008 403096.3659
28118.6667* 6256.724 .002 13690.6341 42546.6992
544390.00* 6256.724 .000 529961.9674 558818.0326
360549.67* 6256.724 .000 346121.6341 374977.6992
-28118.667* 6256.724 .002 -42546.6992 -13690.6341
516271.33* 6256.724 .000 501843.3008 530699.3659
-155721.67* 6256.724 .000 -170149.6992 -141293.6341
-544390.00* 6256.724 .000 -558818.0326 -529961.9674
-516271.33* 6256.724 .000 -530699.3659 -501843.3008
(J) SAMPLES
BF Antib
BF Contr
Control
Antibody
BF Contr
Control
Antibody
BF Antib
Control
Antibody
BF Antib
BF Contr
(I) SAMPLES
Antibody
BF Antib
BF Contr
Control
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
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Table A-20: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the effect of Triton-X-100 on baby formula control and antibody samples. 
 
 
 
Descriptives
INTENSIT
3 327150.7 11297.58577 6522.664 299085.9078 355215.4255
3 383919.0 12462.61317 7195.293 352960.1526 414877.8474
3 477219.7 5632.56889 3251.965 463227.5899 491211.7435
3 471367.7 21305.31869 12300.63 418442.3211 524293.0123
3 482852.7 14766.05896 8525.188 446171.7427 519533.5906
3 560683.3 16849.14364 9727.858 518827.7402 602538.9265
18 450532.2 78401.18543 18479.34 411544.1744 489520.1589
1.00
2.00
3.00
4.00
5.00
6.00
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
ANOVA
INTENSIT
1.02E+11 5 2.039E+10 96.294 .000
2.54E+09 12 211754124.4
1.04E+11 17
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 144
Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-87448.667* 11881.47 .000 -113336.1739 -61561.1594
-93300.667* 11881.47 .000 -119188.1739 -67413.1594
-98933.667* 11881.47 .000 -124821.1739 -73046.1594
-176764.33* 11881.47 .000 -202651.8406 -150876.8261
56768.3333* 11881.47 .000 30880.8261 82655.8406
87448.6667* 11881.47 .000 61561.1594 113336.1739
-5852.0000 11881.47 .631 -31739.5072 20035.5072
-11485.000 11881.47 .353 -37372.5072 14402.5072
-89315.667* 11881.47 .000 -115203.1739 -63428.1594
144217.00* 11881.47 .000 118329.4928 170104.5072
93300.6667* 11881.47 .000 67413.1594 119188.1739
5852.0000 11881.47 .631 -20035.5072 31739.5072
-5633.0000 11881.47 .644 -31520.5072 20254.5072
-83463.667* 11881.47 .000 -109351.1739 -57576.1594
150069.00* 11881.47 .000 124181.4928 175956.5072
98933.6667* 11881.47 .000 73046.1594 124821.1739
11485.0000 11881.47 .353 -14402.5072 37372.5072
5633.0000 11881.47 .644 -20254.5072 31520.5072
-77830.667* 11881.47 .000 -103718.1739 -51943.1594
155702.00* 11881.47 .000 129814.4928 181589.5072
176764.33* 11881.47 .000 150876.8261 202651.8406
89315.6667* 11881.47 .000 63428.1594 115203.1739
83463.6667* 11881.47 .000 57576.1594 109351.1739
77830.6667* 11881.47 .000 51943.1594 103718.1739
233532.67* 11881.47 .000 207645.1594 259420.1739
-56768.333* 11881.47 .000 -82655.8406 -30880.8261
-144217.00* 11881.47 .000 -170104.5072 -118329.4928
-150069.00* 11881.47 .000 -175956.5072 -124181.4928
-155702.00* 11881.47 .000 -181589.5072 -129814.4928
-233532.67* 11881.47 .000 -259420.1739 -207645.1594
(J) SAMPLES
BF Ab
BF Cont
BF TRT C
BFTRTAb
Control
Antibody
BF Cont
BF TRT C
BFTRTAb
Control
Antibody
BF Ab
BF TRT C
BFTRTAb
Control
Antibody
BF Ab
BF Cont
BFTRTAb
Control
Antibody
BF Ab
BF Cont
BF TRT C
Control
Antibody
BF Ab
BF Cont
BF TRT C
BFTRTAb
(I) SAMPLES
Antibody
BF Ab
BF Cont
BF TRT C
BFTRTAb
Control
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
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Table A-21: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the effect of baby formula concentration on control and antibody samples. 
Descriptives
3 16.9267 3.18550 1.83915 9.0134 24.8399
3 15.6400 4.42553 2.55508 4.6464 26.6336
3 13.7833 5.76125 3.32626 -.5284 28.0951
3 8.2800 2.65667 1.53383 1.6805 14.8795
12 13.6575 4.96001 1.43183 10.5061 16.8089
3 459698.3 11763.06212 6791.407 430477.2671 488919.3995
3 623304.3 18207.19046 10511.93 578075.1649 668533.5018
3 1090000 60827.62530 35118.85 938895.8021 1241104.198
3 1336667 15275.25232 8819.171 1298720.836 1374612.497
12 877417.3 368571.95790 106397.6 643237.8837 1111596.783
.00
1.31
5.24
9.17
Total
.00
1.31
5.24
9.17
Total
DIFFEREN
INTENSIT
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
 
 
 
ANOVA
130.653 3 43.551 2.489 .135
139.965 8 17.496
270.619 11
1.49E+12 3 4.952E+11 449.821 .000
8.81E+09 8 1100801187
1.49E+12 11
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
DIFFEREN
INTENSIT
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
LSD
1.2867 3.41523 .716 -6.5889 9.1622
3.1433 3.41523 .384 -4.7322 11.0189
8.6467* 3.41523 .035 .7711 16.5222
-1.2867 3.41523 .716 -9.1622 6.5889
1.8567 3.41523 .602 -6.0189 9.7322
7.3600 3.41523 .063 -.5155 15.2355
-3.1433 3.41523 .384 -11.0189 4.7322
-1.8567 3.41523 .602 -9.7322 6.0189
5.5033 3.41523 .146 -2.3722 13.3789
-8.6467* 3.41523 .035 -16.5222 -.7711
-7.3600 3.41523 .063 -15.2355 .5155
-5.5033 3.41523 .146 -13.3789 2.3722
-163606.00* 27089.99 .000 -226075.6247 -101136.3753
-630301.67* 27089.99 .000 -692771.2914 -567832.0420
-876968.33* 27089.99 .000 -939437.9580 -814498.7086
163606.00* 27089.99 .000 101136.3753 226075.6247
-466695.67* 27089.99 .000 -529165.2914 -404226.0420
-713362.33* 27089.99 .000 -775831.9580 -650892.7086
630301.67* 27089.99 .000 567832.0420 692771.2914
466695.67* 27089.99 .000 404226.0420 529165.2914
-246666.67* 27089.99 .000 -309136.2914 -184197.0420
876968.33* 27089.99 .000 814498.7086 939437.9580
713362.33* 27089.99 .000 650892.7086 775831.9580
246666.67* 27089.99 .000 184197.0420 309136.2914
(J) CONC
1.31
5.24
9.17
.00
5.24
9.17
.00
1.31
9.17
.00
1.31
5.24
1.31
5.24
9.17
.00
5.24
9.17
.00
1.31
9.17
.00
1.31
5.24
(I) CONC
.00
1.31
5.24
9.17
.00
1.31
5.24
9.17
Dependent Variable
DIFFEREN
INTENSIT
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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Table A-22: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the Prion detection in 1.31mg/ml baby formula. 
Descriptive Statistics
Dependent Variable: INTENSIT
530037.9 14073.33107 3
530037.9 14073.33107 3
689873.3 4130.31860 3
689873.3 4130.31860 3
668818.3 4713.31895 3
668818.3 4713.31895 3
652251.7 17793.19596 3
652251.7 17793.19596 3
617960.8 17054.08008 3
617960.8 17054.08008 3
595649.6 2970.66237 3
595649.6 2970.66237 3
566809.6 5569.84422 3
566809.6 5569.84422 3
689873.3 4130.31860 3
617960.8 17054.08008 3
595649.6 2970.66237 3
566809.6 5569.84422 3
668818.3 4713.31895 3
652251.7 17793.19596 3
530037.9 14073.33107 3
617343.0 55270.48675 21
NAME
CONTROL
Total
0PRP
Total
2PRP
Total
5PRP
Total
10PRP
Total
15PRP
Total
20PRP
Total
0PRP
10PRP
15PRP
20PRP
2PRP
5PRP
CONTROL
Total
NUMBER
.00
1.00
2.00
3.00
4.00
5.00
6.00
Total
Mean Std. Deviation N
 
 
ANOVA
INTENSIT
5.93E+10 6 9887882012 78.243 .000
1.77E+09 14 126374432.0
6.11E+10 20
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
71912.5000* 9178.759 .000 52226.0194 91598.9806
94223.7500* 9178.759 .000 74537.2694 113910.2306
123063.75* 9178.759 .000 103377.2694 142750.2306
21055.0000* 9178.759 .038 1368.5194 40741.4806
37621.6667* 9178.759 .001 17935.1860 57308.1473
159835.42* 9178.759 .000 140148.9360 179521.8973
-71912.500* 9178.759 .000 -91598.9806 -52226.0194
22311.2500* 9178.759 .029 2624.7694 41997.7306
51151.2500* 9178.759 .000 31464.7694 70837.7306
-50857.500* 9178.759 .000 -70543.9806 -31171.0194
-34290.833* 9178.759 .002 -53977.3140 -14604.3527
87922.9167* 9178.759 .000 68236.4360 107609.3973
-94223.750* 9178.759 .000 -113910.2306 -74537.2694
-22311.250* 9178.759 .029 -41997.7306 -2624.7694
28840.0000* 9178.759 .007 9153.5194 48526.4806
-73168.750* 9178.759 .000 -92855.2306 -53482.2694
-56602.083* 9178.759 .000 -76288.5640 -36915.6027
65611.6667* 9178.759 .000 45925.1860 85298.1473
-123063.75* 9178.759 .000 -142750.2306 -103377.2694
-51151.250* 9178.759 .000 -70837.7306 -31464.7694
-28840.000* 9178.759 .007 -48526.4806 -9153.5194
-102008.75* 9178.759 .000 -121695.2306 -82322.2694
-85442.083* 9178.759 .000 -105128.5640 -65755.6027
36771.6667* 9178.759 .001 17085.1860 56458.1473
-21055.000* 9178.759 .038 -40741.4806 -1368.5194
50857.5000* 9178.759 .000 31171.0194 70543.9806
73168.7500* 9178.759 .000 53482.2694 92855.2306
102008.75* 9178.759 .000 82322.2694 121695.2306
16566.6667 9178.759 .093 -3119.8140 36253.1473
138780.42* 9178.759 .000 119093.9360 158466.8973
-37621.667* 9178.759 .001 -57308.1473 -17935.1860
34290.8333* 9178.759 .002 14604.3527 53977.3140
56602.0833* 9178.759 .000 36915.6027 76288.5640
85442.0833* 9178.759 .000 65755.6027 105128.5640
-16566.667 9178.759 .093 -36253.1473 3119.8140
122213.75* 9178.759 .000 102527.2694 141900.2306
-159835.42* 9178.759 .000 -179521.8973 -140148.9360
-87922.917* 9178.759 .000 -107609.3973 -68236.4360
-65611.667* 9178.759 .000 -85298.1473 -45925.1860
-36771.667* 9178.759 .001 -56458.1473 -17085.1860
-138780.42* 9178.759 .000 -158466.8973 -119093.9360
-122213.75* 9178.759 .000 -141900.2306 -102527.2694
(J) NAME
10PRP
15PRP
20PRP
2PRP
5PRP
CONTROL
0PRP
15PRP
20PRP
2PRP
5PRP
CONTROL
0PRP
10PRP
20PRP
2PRP
5PRP
CONTROL
0PRP
10PRP
15PRP
2PRP
5PRP
CONTROL
0PRP
10PRP
15PRP
20PRP
5PRP
CONTROL
0PRP
10PRP
15PRP
20PRP
2PRP
CONTROL
0PRP
10PRP
15PRP
20PRP
2PRP
5PRP
(I) NAME
0PRP
10PRP
15PRP
20PRP
2PRP
5PRP
CONTROL
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
Table A-23: 
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Table A-23: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the Prion detection in 5.14mg/ml baby formula. 
Descriptive Statistics
Dependent Variable: INTENSIT
1102600 10866.92229 3
1102600 10866.92229 3
1009000 4413.61530 3
1009000 4413.61530 3
1010400 3750.99987 3
1010400 3750.99987 3
986351.3 13296.45383 3
986351.3 13296.45383 3
1074933 9027.91966 3
1074933 9027.91966 3
1049400 17129.79860 3
1049400 17129.79860 3
951061.7 10078.25726 3
951061.7 10078.25726 3
951061.7 10078.25726 3
1102600 10866.92229 3
1074933 9027.91966 3
1049400 17129.79860 3
1009000 4413.61530 3
1010400 3750.99987 3
986351.3 13296.45383 3
1026249 50595.32519 21
NUMBER
2.00
Total
5.00
Total
6.00
Total
7.00
Total
3.00
Total
4.00
Total
1.00
Total
1.00
2.00
3.00
4.00
5.00
6.00
7.00
Total
SAMPLES
0Prp
10Prp
15Prp
20Prp
2Prp
5Prp
Control
Total
Mean Std. Deviation N
 
 
ANOVA
INTENSIT
4.96E+10 6 8264643007 71.872 .000
1.61E+09 14 114991469.6
5.12E+10 20
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
93600.0000* 8755.626 .000 74821.0508 112378.9492
92200.0000* 8755.626 .000 73421.0508 110978.9492
116248.67* 8755.626 .000 97469.7174 135027.6159
27666.6667* 8755.626 .007 8887.7174 46445.6159
53200.0000* 8755.626 .000 34421.0508 71978.9492
151538.33* 8755.626 .000 132759.3841 170317.2826
-93600.000* 8755.626 .000 -112378.9492 -74821.0508
-1400.0000 8755.626 .875 -20178.9492 17378.9492
22648.6667* 8755.626 .022 3869.7174 41427.6159
-65933.333* 8755.626 .000 -84712.2826 -47154.3841
-40400.000* 8755.626 .000 -59178.9492 -21621.0508
57938.3333* 8755.626 .000 39159.3841 76717.2826
-92200.000* 8755.626 .000 -110978.9492 -73421.0508
1400.0000 8755.626 .875 -17378.9492 20178.9492
24048.6667* 8755.626 .016 5269.7174 42827.6159
-64533.333* 8755.626 .000 -83312.2826 -45754.3841
-39000.000* 8755.626 .001 -57778.9492 -20221.0508
59338.3333* 8755.626 .000 40559.3841 78117.2826
-116248.67* 8755.626 .000 -135027.6159 -97469.7174
-22648.667* 8755.626 .022 -41427.6159 -3869.7174
-24048.667* 8755.626 .016 -42827.6159 -5269.7174
-88582.000* 8755.626 .000 -107360.9492 -69803.0508
-63048.667* 8755.626 .000 -81827.6159 -44269.7174
35289.6667* 8755.626 .001 16510.7174 54068.6159
-27666.667* 8755.626 .007 -46445.6159 -8887.7174
65933.3333* 8755.626 .000 47154.3841 84712.2826
64533.3333* 8755.626 .000 45754.3841 83312.2826
88582.0000* 8755.626 .000 69803.0508 107360.9492
25533.3333* 8755.626 .011 6754.3841 44312.2826
123871.67* 8755.626 .000 105092.7174 142650.6159
-53200.000* 8755.626 .000 -71978.9492 -34421.0508
40400.0000* 8755.626 .000 21621.0508 59178.9492
39000.0000* 8755.626 .001 20221.0508 57778.9492
63048.6667* 8755.626 .000 44269.7174 81827.6159
-25533.333* 8755.626 .011 -44312.2826 -6754.3841
98338.3333* 8755.626 .000 79559.3841 117117.2826
-151538.33* 8755.626 .000 -170317.2826 -132759.3841
-57938.333* 8755.626 .000 -76717.2826 -39159.3841
-59338.333* 8755.626 .000 -78117.2826 -40559.3841
-35289.667* 8755.626 .001 -54068.6159 -16510.7174
-123871.67* 8755.626 .000 -142650.6159 -105092.7174
-98338.333* 8755.626 .000 -117117.2826 -79559.3841
(J) SAMPLES
10Prp
15Prp
20Prp
2Prp
5Prp
Control
0Prp
15Prp
20Prp
2Prp
5Prp
Control
0Prp
10Prp
20Prp
2Prp
5Prp
Control
0Prp
10Prp
15Prp
2Prp
5Prp
Control
0Prp
10Prp
15Prp
20Prp
5Prp
Control
0Prp
10Prp
15Prp
20Prp
2Prp
Control
0Prp
10Prp
15Prp
20Prp
2Prp
5Prp
(I) SAMPLES
0Prp
10Prp
15Prp
20Prp
2Prp
5Prp
Control
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
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Table A-24: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the effect of Prion concentration on decoy fluorescence. 
Descriptive Statistics
Dependent Variable: DIFFEREN
1.8333 2.17845 3
1.8333 2.17845 3
-4.1233 2.78687 3
-4.1233 2.78687 3
1.9967 6.83714 3
1.9967 6.83714 3
2.4733 7.45156 3
2.4733 7.45156 3
4.7333 4.50891 3
4.7333 4.50891 3
1.8200 5.50564 3
1.8200 5.50564 3
.0000 .00000 3
.0000 .00000 3
.0000 .00000 3
1.8333 2.17845 3
-4.1233 2.78687 3
1.9967 6.83714 3
4.7333 4.50891 3
1.8200 5.50564 3
2.4733 7.45156 3
1.2476 4.83072 21
NUMBER
2.00
Total
3.00
Total
4.00
Total
7.00
Total
5.00
Total
6.00
Total
1.00
Total
1.00
2.00
3.00
4.00
5.00
6.00
7.00
Total
NAME
0.5Prp
0.8Prp
1.0Prp
10.0Prp
2.0Prp
5.0Prp
noPrp
Total
Mean Std. Deviation N
 
 
ANOVA
DIFFEREN
135.864 6 22.644 .958 .487
330.854 14 23.632
466.718 20
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: DIFFEREN
LSD
5.9567 3.96925 .156 -2.5565 14.4699
-.1633 3.96925 .968 -8.6765 8.3499
-.6400 3.96925 .874 -9.1532 7.8732
-2.9000 3.96925 .477 -11.4132 5.6132
.0133 3.96925 .997 -8.4999 8.5265
1.8333 3.96925 .651 -6.6799 10.3465
-5.9567 3.96925 .156 -14.4699 2.5565
-6.1200 3.96925 .145 -14.6332 2.3932
-6.5967 3.96925 .119 -15.1099 1.9165
-8.8567* 3.96925 .043 -17.3699 -.3435
-5.9433 3.96925 .157 -14.4565 2.5699
-4.1233 3.96925 .316 -12.6365 4.3899
.1633 3.96925 .968 -8.3499 8.6765
6.1200 3.96925 .145 -2.3932 14.6332
-.4767 3.96925 .906 -8.9899 8.0365
-2.7367 3.96925 .502 -11.2499 5.7765
.1767 3.96925 .965 -8.3365 8.6899
1.9967 3.96925 .623 -6.5165 10.5099
.6400 3.96925 .874 -7.8732 9.1532
6.5967 3.96925 .119 -1.9165 15.1099
.4767 3.96925 .906 -8.0365 8.9899
-2.2600 3.96925 .578 -10.7732 6.2532
.6533 3.96925 .872 -7.8599 9.1665
2.4733 3.96925 .543 -6.0399 10.9865
2.9000 3.96925 .477 -5.6132 11.4132
8.8567* 3.96925 .043 .3435 17.3699
2.7367 3.96925 .502 -5.7765 11.2499
2.2600 3.96925 .578 -6.2532 10.7732
2.9133 3.96925 .475 -5.5999 11.4265
4.7333 3.96925 .253 -3.7799 13.2465
-.0133 3.96925 .997 -8.5265 8.4999
5.9433 3.96925 .157 -2.5699 14.4565
-.1767 3.96925 .965 -8.6899 8.3365
-.6533 3.96925 .872 -9.1665 7.8599
-2.9133 3.96925 .475 -11.4265 5.5999
1.8200 3.96925 .654 -6.6932 10.3332
-1.8333 3.96925 .651 -10.3465 6.6799
4.1233 3.96925 .316 -4.3899 12.6365
-1.9967 3.96925 .623 -10.5099 6.5165
-2.4733 3.96925 .543 -10.9865 6.0399
-4.7333 3.96925 .253 -13.2465 3.7799
-1.8200 3.96925 .654 -10.3332 6.6932
(J) NAME
0.8Prp
1.0Prp
10.0Prp
2.0Prp
5.0Prp
noPrp
0.5Prp
1.0Prp
10.0Prp
2.0Prp
5.0Prp
noPrp
0.5Prp
0.8Prp
10.0Prp
2.0Prp
5.0Prp
noPrp
0.5Prp
0.8Prp
1.0Prp
2.0Prp
5.0Prp
noPrp
0.5Prp
0.8Prp
1.0Prp
10.0Prp
5.0Prp
noPrp
0.5Prp
0.8Prp
1.0Prp
10.0Prp
2.0Prp
noPrp
0.5Prp
0.8Prp
1.0Prp
10.0Prp
2.0Prp
5.0Prp
(I) NAME
0.5Prp
0.8Prp
1.0Prp
10.0Prp
2.0Prp
5.0Prp
noPrp
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
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Table A-25: Descriptive Statistics, ANOVA and mean comparison (LSD) for 
the effect of detergents on decoy fluorescence. 
Descriptive Statistics
Dependent Variable: INTENSIT
350388.0 17504.71139 3
350388.0 17504.71139 3
365797.0 4327.50425 3
365797.0 4327.50425 3
340073.7 8830.63431 3
340073.7 8830.63431 3
350388.0 17504.71139 3
365797.0 4327.50425 3
340073.7 8830.63431 3
352086.2 15048.90886 9
NUMBER
1.00
Total
2.00
Total
3.00
Total
1.00
2.00
3.00
Total
SAMPLE
buffer
SDS
TRITON
Total
Mean Std. Deviation N
 
 
 
 
 
 
 
 
ANOVA
INTENSIT
1.01E+09 2 502756315.4 3.741 .088
8.06E+08 6 134374105.4
1.81E+09 8
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Multiple Comparisons
Dependent Variable: INTENSIT
LSD
-15409.000 9464.816 .155 -38568.5698 7750.5698
10314.3333 9464.816 .318 -12845.2365 33473.9031
15409.0000 9464.816 .155 -7750.5698 38568.5698
25723.3333* 9464.816 .035 2563.7635 48882.9031
-10314.333 9464.816 .318 -33473.9031 12845.2365
-25723.333* 9464.816 .035 -48882.9031 -2563.7635
(J) SAMPLE
SDS
TRITON
buffer
TRITON
buffer
SDS
(I) SAMPLE
buffer
SDS
TRITON
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
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Appendix B 
Data Tables 
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pH Values Intensity Values 
(counts/sec) 
Coefficient of Variation 
5.00 7046.45 7.00% 
5.00 6548.00  
5.00 6126.59  
6.00 48785.40 1.72% 
6.00 47155.10  
6.00 48214.50  
7.00 69602.70 1.10% 
7.00 68531.80  
7.00 70007.10  
8.00 99592.40 1.47% 
8.00 97572.70  
8.00 96801.80  
9.00 105234.00 2.11% 
9.00 100915.00  
9.00 102622.00  
10.00 55917.30 2.54% 
10.00 53773.60  
10.00 53338.30  
 
Table (B-1): pH dependence of decoy in phosphate buffer solution. 
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Solvent Intensity (counts/sec) 
Phosphate Buffer 69602.70 
Phosphate Buffer 68531.80 
Phosphate Buffer 70007.10 
Ethyl Alcohol 73826.70 
Ethyl Alcohol 72781.10 
Ethyl Alcohol 71708.40 
DMSO 21727.40 
DMSO 21953.80 
DMSO 21450.90 
 
Table (B-2): Dependence of fluoresce on the polarity of the solvent. 
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pH Values Samples Intensity 
(counts/sec) 
% Difference of 
intensity 
(counts/sec) 
6.00 Control 65939.60  
6.00 Control 65243.00  
6.00 Control 64391.50  
6.00 Antibody 59565.20 -9.67% 
6.00 Antibody 58836.50 -9.82% 
6.00 Antibody 58778.10 -8.72% 
7.00 Control 90935.40  
7.00 Control 89577.00  
7.00 Control 88244.10  
7.00 Antibody 130097.0 43.07% 
7.00 Antibody 126553.0 41.28% 
7.00 Antibody 122433.0 38.74% 
8.00 Control 135670.0  
8.00 Control 132334.0  
8.00 Control 129929.0  
8.00 Antibody 174266.0 28.45% 
8.00 Antibody 166488.0 25.81% 
8.00 Antibody 167481.0 28.90% 
. 
Table (B-3): Effect of pH on the % difference of intensity between control and antibody samples. 
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Time (Hours) Control Intensity 
Values (Average) 
(counts/sec) 
Antibody Intensity 
Values (Average) 
(counts/sec) 
% Difference of 
intensity 
(counts/sec) 
0.00 38084.30 44536.20 16.94 
1.00 35938.60 47376.30 31.83 
2.00 38763.40 46494.80 19.95 
4.00 37158.80 48081.60 29.39 
5.00 39861.30 46960.40 17.81 
10.00 39488.00 47614.50 20.58 
20.00 32101.87 37832.09 18.85 
 
Table (B-4): Kinetic Study for antibody decoy reaction. Equilibrium time was less than 4 hours. 
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 Sample Intensity (counts/sec) Average % Difference in 
intensity from control 
(counts/sec) 
Control 53674.20  
Control 53163.50  
Control 51717.90  
Antibody Sample 80421.10 56.79 
Antibody Sample 84062.40  
Antibody Sample 84120.10  
BSA Sample 50420.50 0.28 
BSA Sample 52197.40  
BSA Sample 56380.60  
 
Table (B-5): Specificity of reaction between antibody and decoy. BSA does have the same 
effect. 
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Antibody Concentration 
(nM) 
Average Intensity 
(counts/sec) 
Average % Difference from 
0 antibody sample 
(counts/sec) 
0.00 57090.29 0.00 
1.00 79998.70 40.13 
2.00 91191.57 59.73 
4.00 89298.97 56.42 
5.00 89517.93 56.80 
8.00 92060.47 61.25 
20.00 93775.27 64.26 
55.00 97514.30 70.81 
88.00 109684.00 92.12 
110.00 118865.00 108.21 
 
Table (B-6): Effect of antibody concentration on decoy fluorescence. Data was analyzed to 
determine equilibrium constant value for the reaction between antibody and decoy. 
 
 
 
 
 
 
 
 
 
 
 
 
 162
Time(Hours) Average Control 
Intensity 
(counts/sec) 
Antibody Sample 
Intensity 
(counts/sec) 
Antibody and Prion 
Sample Intensity 
(counts/sec) 
0.00 72201.57 94951.57 84370.67 
2.00 74123.70 101316.74 86229.83 
4.00 76325.83 106597.92 80312.50 
11.00 66913.60 102696.45 81007.63 
 
Table (B-7): Prion detection kinetic study. Equilibrium time for the reaction was less than 4 
hours. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Control - 49736.20 
Control - 48200.80 
Control - 48805.90 
Antibody 0.00 61512.20 
Antibody 0.00 62730.90 
Antibody 0.00 61513.20 
Antibody and Prion 2.00 60273.60 
Antibody and Prion 2.00 60342.40 
Antibody and Prion 2.00 61746.20 
Antibody and Prion 4.00 60786.20 
Antibody and Prion 4.00 62985.70 
Antibody and Prion 4.00 61264.40 
Antibody and Prion 8.00 56693.00 
Antibody and Prion 8.00 57548.10 
Antibody and Prion 8.00 56243.40 
Antibody and Prion 10.00 54411.30 
Antibody and Prion 10.00 54617.10 
Antibody and Prion 10.00 54305.00 
Antibody and Prion 20.00 53136.10 
Antibody and Prion 20.00 53341.80 
Antibody and Prion 20.00 53132.70 
 
Table (B-8): Prion detection data in 0.1M phosphate buffer. Decoy and antibody concentration 
was 4nM. 
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Sample Prion Concentration (nM) Intensity Values 
(counts/sec) 
Control - 36002.00 
Control - 36477.60 
Control - 41798.80 
Antibody 0.00 52587.90 
Antibody 0.00 52248.80 
Antibody 0.00 52492.00 
Antibody and Prion 2.00 49011.10 
Antibody and Prion 2.00 50889.40 
Antibody and Prion 2.00 48344.40 
Antibody and Prion 3.00 45567.10 
Antibody and Prion 3.00 46984.30 
Antibody and Prion 3.00 42006.60 
Antibody and Prion 4.00 46372.90 
Antibody and Prion 4.00 46171.40 
Antibody and Prion 4.00 39816.90 
Antibody and Prion 7.00 46239.70 
Antibody and Prion 7.00 44594.50 
Antibody and Prion 7.00 44864.10 
Antibody and Prion 8.00 39503.80 
Antibody and Prion 8.00 39255.40 
Antibody and Prion 8.00 40450.10 
 
Table (B-9): Prion detection data in 0.1M phosphate buffer. Antibody and decoy concentration 
was 4nM. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Control - 47568.50 
Control - 46670.00 
Control - 51813.80 
Antibody 0.00 31448.90 
Antibody 0.00 32011.50 
Antibody 0.00 30188.70 
Antibody and Prion 0.20 23538.80 
Antibody and Prion 0.20 23211.50 
Antibody and Prion 0.20 22398.40 
Antibody and Prion 0.50 27609.80 
Antibody and Prion 0.50 28570.60 
Antibody and Prion 0.50 28479.20 
Antibody and Prion 1.00 30991.40 
Antibody and Prion 1.00 29917.70 
Antibody and Prion 1.00 28249.10 
Antibody and Prion 2.00 34623.40 
Antibody and Prion 2.00 35146.20 
Antibody and Prion 2.00 34355.20 
Antibody and Prion 5.00 32136.90 
Antibody and Prion 5.00 31930.10 
Antibody and Prion 5.00 31713.20 
Antibody and Prion 8.00 47008.20 
Antibody and Prion 8.00 47387.40 
Antibody and Prion 8.00 46813.50 
 
Table (B-10): Prion detection data in 0.1M phosphate buffer. Decoy and antibody concentration 
was 1 nM. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Gelatin Control - 38075.10 
Gelatin Control - 37422.40 
Gelatin Control - 37959.50 
Gelatin Antibody 0.00 47800.90 
Gelatin Antibody 0.00 47619.80 
Gelatin Antibody 0.00 46512.90 
Gelatin Antibody Prion 2.00 46485.60 
Gelatin Antibody Prion 2.00 46560.80 
Gelatin Antibody Prion 2.00 44560.30 
Gelatin Antibody Prion 4.00 44280.60 
Gelatin Antibody Prion 4.00 43182.50 
Gelatin Antibody Prion 4.00 41795.40 
Gelatin Antibody Prion 8.00 43356.40 
Gelatin Antibody Prion 8.00 45430.60 
Gelatin Antibody Prion 8.00 44018.00 
Gelatin Antibody Prion 10.00 40685.00 
Gelatin Antibody Prion 10.00 41757.90 
Gelatin Antibody Prion 10.00 40174.30 
 
Table (B-11): Prion detection data in 0.01mg/ml gelatin solution. Decoy and antibody 
concentration was 4nM.  
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Gelatin Control - 170769.00 
Gelatin Control - 165687.00 
Gelatin Control - 167010.00 
Gelatin Antibody 0.00 183336.00 
Gelatin Antibody 0.00 183299.00 
Gelatin Antibody 0.00 192324.00 
Gelatin Antibody Prion 2.00 169690.00 
Gelatin Antibody Prion 2.00 163833.00 
Gelatin Antibody Prion 2.00 171339.00 
Gelatin Antibody Prion 4.00 162740.00 
Gelatin Antibody Prion 4.00 163073.00 
Gelatin Antibody Prion 4.00 162997.00 
Gelatin Antibody Prion 8.00 162758.00 
Gelatin Antibody Prion 8.00 163055.00 
Gelatin Antibody Prion 8.00 156772.00 
Gelatin Antibody Prion 10.00 165738.00 
Gelatin Antibody Prion 10.00 160556.00 
Gelatin Antibody Prion 10.00 157995.00 
Gelatin Antibody Prion 20.00 165364.00 
Gelatin Antibody Prion 20.00 164803.00 
Gelatin Antibody Prion 20.00 164437.00 
 
Table (B-12): Prion detection data in 0.4mg/ml gelatin solution. Decoy and antibody 
concentration was 4nM.  
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Gelatin Control - 170487.99 
Gelatin Control - 172644.21 
Gelatin Control - 164488.32 
Gelatin Antibody 0.00 204104.61 
Gelatin Antibody 0.00 204275.52 
Gelatin Antibody 0.00 206804.34 
Gelatin Antibody Prion 0.50 196413.66 
Gelatin Antibody Prion 0.50 194109.21 
Gelatin Antibody Prion 0.50 195859.62 
Gelatin Antibody Prion 0.80 188546.94 
Gelatin Antibody Prion 0.80 186579.45 
Gelatin Antibody Prion 0.80 190152.36 
Gelatin Antibody Prion 1.00 179662.86 
Gelatin Antibody Prion 1.00 178400.88 
Gelatin Antibody Prion 1.00 180292.23 
Gelatin Antibody Prion 2.00 183837.60 
Gelatin Antibody Prion 2.00 179512.20 
Gelatin Antibody Prion 2.00 176089.95 
Gelatin Antibody Prion 5.00 169876.44 
Gelatin Antibody Prion 5.00 180895.68 
Gelatin Antibody Prion 5.00 172316.97 
 
Table (B-13): Prion detection data in 0.4mg/ml gelatin and 0.3mg/ml SDS solution. Decoy and 
antibody concentration was 4nM. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Gelatin Control - 169402.80 
Gelatin Control - 171820.30 
Gelatin Control - 163492.40 
Gelatin Antibody 0.00 224029.70 
Gelatin Antibody 0.00 215841.40 
Gelatin Antibody 0.00 210327.60 
Gelatin Antibody Prion 0.50 217294.60 
Gelatin Antibody Prion 0.50 209497.70 
Gelatin Antibody Prion 0.50 206932.30 
Gelatin Antibody Prion 0.80 209259.10 
Gelatin Antibody Prion 0.80 206377.90 
Gelatin Antibody Prion 0.80 212721.60 
Gelatin Antibody Prion 1.00 198791.00 
Gelatin Antibody Prion 1.00 195254.60 
Gelatin Antibody Prion 1.00 199411.00 
Gelatin Antibody Prion 2.00 193519.20 
Gelatin Antibody Prion 2.00 186281.80 
Gelatin Antibody Prion 2.00 191399.00 
Gelatin Antibody Prion 5.00 179041.00 
Gelatin Antibody Prion 5.00 182117.00 
Gelatin Antibody Prion 5.00 175203.80 
 
Table (B-14): Prion detection data in 1.0mg/ml gelatin and 0.3mg/ml SDS solution. Decoy and 
antibody concentration was 4nM. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Gelatin Control - 170554.81 
Gelatin Control - 169412.45 
Gelatin Control - 171275.47 
Gelatin Antibody 0.00 192725.42 
Gelatin Antibody 0.00 184988.00 
Gelatin Antibody 0.00 187253.84 
Gelatin Antibody Prion 0.50 191487.61 
Gelatin Antibody Prion 0.50 185550.27 
Gelatin Antibody Prion 0.50 187071.32 
Gelatin Antibody Prion 0.80 192400.23 
Gelatin Antibody Prion 0.80 187346.15 
Gelatin Antibody Prion 0.80 191572.57 
Gelatin Antibody Prion 1.00 191296.68 
Gelatin Antibody Prion 1.00 185385.57 
Gelatin Antibody Prion 1.00 187090.19 
Gelatin Antibody Prion 2.00 179967.48 
Gelatin Antibody Prion 2.00 172004.53 
Gelatin Antibody Prion 2.00 178172.65 
Gelatin Antibody Prion 5.00 172992.68 
Gelatin Antibody Prion 5.00 168604.72 
Gelatin Antibody Prion 5.00 170360.74 
 
Table (B-15): Prion detection data in 2mg/ml gelatin and 0.3mg/ml SDS. Decoy and antibody 
concentration was 4nM. 
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Decoy Concentration (nM) Intensity Values 
(counts/sec) 
163.00 335665.00 
140.00 335665.00 
116.67 295708.00 
93.30 259776.00 
70.00 227128.00 
23.30 132823.00 
18.67 123135.00 
16.33 122195.00 
11.67 115774.00 
9.33 129862.00 
7.00 93973.10 
4.67 110543.00 
0.00 112551.00 
 
Table (B-16): Decoy fluorescence in full strength baby formula. 
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Decoy Concentration (nM) Intensity Values 
(counts/sec) 
163.00 811656.00 
140.00 707895.00 
116.67 607177.00 
93.30 489990.00 
70.00 393762.00 
23.30 75554.00 
18.67 59936.00 
16.33 48984.00 
9.33 35525.00 
7.00 25633.00 
4.67 13240.00 
0.00 0.00 
 
Table (B-17): Decoy fluorescence in 20 times diluted baby formula. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 173
 
Intensity Values (counts/sec) 
 
Decoy 
Concentration (nM) 
40 times Diluted 5000 times diluted Buffer 
163.00 1100000.00 1040000.00 1030000.00 
140.00 958895.00 893005.00 733295.00 
116.67 815669.00 781505.00 688727.00 
93.30 644666.00 608677.00 594912.00 
70.00 475565.00 483398.00 441606.00 
23.30 109933.00 134795.00 78946.00 
18.67 80190.00 103596.00 66312.00 
16.33 79063.00 86941.00 46222.00 
11.67 61235.00 62958.00 39093.00 
9.33 40295.00 52580.00 27989.00 
7.00 24449.00 33507.00 25740.00 
4.67 19311.00 22150.00 15748.00 
0.00 0.00 0.00 0.00 
 
Table (B-18): Effect of baby formula concentration on decoy fluorescence. 
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Samples Intensity Values (counts/sec) 
Buffer Control 331453.00 
Buffer Control 335665.00 
Buffer Control 314334.00 
Antibody 382126.00 
Antibody 397181.00 
Antibody 372450.00 
Baby formula control 478656.00 
Baby formula control 471008.00 
Baby formula control 481995.00 
Baby formula Antibody 448260.00 
Baby formula Antibody 475611.00 
Baby formula Antibody 490232.00 
Baby formula Triton control 494444.00 
Baby formula Triton control 487886.00 
Baby formula Triton control 466228.00 
Baby formula Triton antibody 576124.00 
Baby formula Triton antibody 542712.00 
Baby formula Triton antibody 563214.00 
 
Table (B-19): Effect of Triton-X-100 on the percentage differences between control and antibody 
samples of baby formula. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Baby formula control - 534371.25 
Baby formula control - 514307.50 
Baby formula control - 541435.00 
Baby formula antibody  0.00 693923.80 
Baby formula antibody 0.00 690028.80 
Baby formula antibody 0.00 685667.50 
Baby formula antibody and Prion 2.00 673986.30 
Baby formula antibody and Prion 2.00 667712.50 
Baby formula antibody and Prion 2.00 664756.30 
Baby formula antibody and Prion 5.00 643861.30 
Baby formula antibody and Prion 5.00 640205.00 
Baby formula antibody and Prion 5.00 672688.80 
Baby formula antibody and Prion 10.00 634708.80 
Baby formula antibody and Prion 10.00 618557.50 
Baby formula antibody and Prion 10.00 600616.30 
Baby formula antibody and Prion 15.00 598210.00 
Baby formula antibody and Prion 15.00 596346.30 
Baby formula antibody and Prion 15.00 592392.50 
Baby formula antibody and Prion 20.00 560433.80 
Baby formula antibody and Prion 20.00 570728.80 
Baby formula antibody and Prion 20.00 569266.30 
 
Table (B-20): Prion detection data in 1.31mg/ml baby formula with 0.454mg/ml Triton-X100. 
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Samples Prion Concentration (nM) Intensity Values 
(counts/sec) 
Baby formula control - 962211.00 
Baby formula control - 948375.00 
Baby formula control - 942599.00 
Baby formula antibody  0.00 1095400.00 
Baby formula antibody 0.00 1115100.00 
Baby formula antibody 0.00 1097300.00 
Baby formula antibody and Prion 2.00 1085300.00 
Baby formula antibody and Prion 2.00 1068800.00 
Baby formula antibody and Prion 2.00 1070700.00 
Baby formula antibody and Prion 5.00 1050100.00 
Baby formula antibody and Prion 5.00 1055300.00 
Baby formula antibody and Prion 5.00 1062800.00 
Baby formula antibody and Prion 10.00 1013600.00 
Baby formula antibody and Prion 10.00 1008600.00 
Baby formula antibody and Prion 10.00 1004800.00 
Baby formula antibody and Prion 15.00 1014200.00 
Baby formula antibody and Prion 15.00 1010300.00 
Baby formula antibody and Prion 15.00 1006700.00 
Baby formula antibody and Prion 20.00 998597.00 
Baby formula antibody and Prion 20.00 972208.00 
Baby formula antibody and Prion 20.00 988249.00 
 
Table (B-21): Prion detection data in 5.34mg/ml baby formula with 0.454mg/ml Triton-X100. 
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Sample Prion Concentration (nM) Intensity Values 
(counts/sec) 
Decoy 0.00 140021.00 
Decoy 0.00 133640.00 
Decoy 0.00 136503.00 
Decoy and Prion 0.50 141653.00 
Decoy and Prion 0.50 139828.00 
Decoy and Prion 0.50 143739.00 
Decoy and Prion 0.80 138565.00 
Decoy and Prion 0.80 141514.00 
Decoy and Prion 0.80 130410.00 
Decoy and Prion 1.00 132619.00 
Decoy and Prion 1.00 126504.00 
Decoy and Prion 1.00 128567.00 
Decoy and Prion 2.00 137203.00 
Decoy and Prion 2.00 137081.00 
Decoy and Prion 2.00 141152.00 
Decoy and Prion 5.00 147970.00 
Decoy and Prion 5.00 132769.00 
Decoy and Prion 5.00 142634.00 
Decoy and Prion 10.00 139634.00 
Decoy and Prion 10.00 136831.00 
Decoy and Prion 10.00 139634.00 
 
Table (B-22): Effect of Prion concentration on decoy fluorescence. Decoy concentration was 4 
nM and experiment was done in phosphate buffer. 
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Intensity Values (counts/sec) 
Decoy and Buffer Decoy and SDS Decoy and Triton-X-100 
359893.00 360993.00 339610.00 
330187.00 369390.00 331484.00 
361084.00 367008.00 349127.00 
 
Table (B-23): Effect of buffer, SDS and Triton-X-100 on the decoy fluorescence. Decoy 
concentration was 10 nM. 
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Ingredients of Baby formula 
Whey protein concentrate (Cow’s milk) 
Vegetable’s oil 
Lactose 
Corn maltodextrin 
Minerals (Potassium citrate, Calcium chloride, Calcium 
phosphate, Potassium phosphate, Sodium citrate, 
Magnesium chloride, Ferrous sulfate, Zinc sulfate, 
Sodium chloride, Copper sulfate, Potassium iodide, 
Manganese sulfate) 
Soy lecithin 
Vitamins ( Sodium ascorbate, Inositol, Choline bitartrate, 
Alpha-tocopheryl acetate, Niacinamide, Calcium 
pantothenate, Riboflavin, Vitamin A acetate, Pyridoxine 
hydrochloride, Thiamine mononitrate, Folic acid, 
Phylloquinone, Biotin, Vitamin D3, Vitamin B12
Taurine 
Nucleotides ( Cytidine 5-monophosphate, Disodium 
uridine 5- monophosphate, Adenosine 5- 
monophosphate, Disodium guanosine 5- 
monophosphate) 
L-cartinine 
 
Table (B-24): Ingredients of Good Start brand Nestle baby formula 
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